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1 General introduction: 
1.1 Mycophenolic acid  
Mycophenolic acid (MPA) is an active agent of Penicillium brevicopactum and was discovered 
by an Italian physician Bartolomeo Gosio in 1893 as an antibiotic against Bacillus anthracis. 
Currently, MPA is available in two generic forms (enteric-coated mycophenolate sodium (EC-
MPS) myfortic®; Novartis Pharma AG, Basel, Switzerland; and mycophenolate mofetil (MMF); 
CellCept, Roche, Grenzach-Wyhlen, Germany) and is prescribed to the organ transplanted 
patients with the aims to prevent allograft rejection [1;2].    
1.1.1 Pharmacodynamics of MPA 
Proliferating cells require pools of nucleotides including guanosine monophosphate (GMP) 
during DNA replication. Inosine monophosphate dehydrogenase (IMPDH)-2 is involved in the 
conversion of inosine monophosphate (IMP) into GMP via de novo pathway [3]. Highly 
proliferating cells such as B- and T-lymphocytes largely depends on the de novo pathway for the 
GMP synthesis [1]. However non-lymphocytes mainly acquire GMP via salvage pathway, where 
GMP is obtained from breaking down of RNA and DNA [1]. IMPDH-1 is expressed in all most 
all cell types, while IMPDH-2 is mainly expressed in proliferating active lymphocytes [1]. MPA 
competitively and reversibly inhibits the enzymatic activity of IMPDH-2 fivefold more than 
IMPDH-1, making it an effective immunosuppressive drug (ISD) (Fig. 1) [2]. MPA can prevent 
allograft rejection via three mechanisms: a) by inducing apoptosis in activated T-lymphocytes, 
consequently reduces clones of cells that respond to antigenic stimulation, b) by suppressing 
glycosylation and expression of some adhesion molecules, as a result, recruitment of immune 
cells decreases at the site of graft, and c) by depleting the cofactor of the inducible form of nitric 
oxide synthase „tetrahydrobiopterin‟, in turn suppresses the production of NO and consequently 
peroxynitrite mediated tissue damage [1].  
MPA has found its use in the treatment of autoimmune disorders (eyes and skin) [9;10], 
hypertension [11], lupus nephritis [3] as well as in neuromuscular autoimmune diseases [13;14]. 
As organ transplanted patients undergoing immunosuppressive therapy are more susceptible to 
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the infectious agents [4], the anti-bacterial [5], anti-viral [6] and anti-fungal [7] activities of MPA 
make it as a drug of choice for organ transplanted patients. 
1.1.2 Pharmacokinetics 
 Upon oral administration, MMF is rapidly hydrolyzed by esterases into active form MPA and is 
absorbed in the stomach [8]. The EC-MPS requires neutral pH of intestine for solubility rather 
than acidic pH of stomach and is absorbed in small intestine [15;16]. MPA maximal plasma 
concentration (Cmax) is acquired within 1.5-2.5 hrs after oral administration with mean 
bioavailability of 72% in case of EC-MPS [8]. While in the case of MMF, approximately 1-1.5 
hrs is required to achieve Cmax with mean bioavailability of 81% - 94 % [8]. Trough plasma 
concentration of MPA in the range of 1.0-3.5 mg/L indicates adequate therapy in liver transplant 
recipients [9]. Approximately 97-99 % MPA binds to the plasma albumin and less than three 
percent remains unbound which is responsible for the therapeutic activity in renal and heart 
transplanted patients [10].    
MPA toxicity is reduced and excretion rate is increased by undergoing glucuronidation as a 
phase II metabolism. MPA is rapidly metabolized into MPA glucuronide (MPAG) by uridine 
diphosphate-glucuronosyltransferase (UGT), 7-O-glucoside by UGT287, acyl glucuronide MPA 
(AcMPAG) by UGTs (1A9, 1A7, 1A8, 1A10), and 6-O-desmethyl MPA by cytochrome P-450 
3A45 enzyme which are expressed in liver, gastrointestinal (GI) tract and in kidney cells [19-21].  
Following oral administration, the mean elimination half-life of MPA is ranged between 9 to 17 
hrs [8]. Excretion of MPA mostly occurs through urine in MPAG (60-93%) metabolite form and 
approximately ≤3% as MPA. Less than 6% is eliminated along with feces. Some portion of 
MPAG is recycled via enterohepatic circulation process. In this process MPAG is excreted from 
the liver cells in bile via multidrug resistance protein 2 (MRP2). GI tract bacteria 
deglucuronidate MPAG and convert it to MPA [5;22] which is again absorbed to the blood and is 
responsible for the second peak of MPA detected in plasma 6-12 hrs following oral 
administration [11]. 
1.1.3 Adverse side effects of MPA 
On the one side, MPA is important for the prevention of allograft rejection, while on the other 
side its use is associated with some adverse effects  such as nerurological disturbances, cardio-
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respiratory toxicity, metabolic disturbances, hematologic effects and gastrointestinal (GI) tract 
complications including diarrhea [4].  
MPA-induced diarrhea of unknown etiology is frequently observed in transplanted patients, 
which results in dehydration and discomfort in the immune compromised patients ([28;29]). 
Approximately 62% and 79% of diarrhea incidences occurred in kidney transplanted patients 
following MMF and EC-MPA therapy, respectively [12]. Reducing the dose can decrease the 
chances of diarrhea incidence but concomitantly can increase the chances of acute allograft 
rejection [13]. It is difficult to assess quantitatively the overall diarrheogenic potential because 
drug based specific toxic effects cannot be dissociated from the potential contribution of other 
possible factors such as drug-drug interaction [13] and food-drug interactions [14] etc. Therefore 
it is necessary to investigate and understand the cellular mechanisms of MPA-induced diarrhea 
and to explore possible anti-diarrheal inhibitor(s) to use as a therapeutic agent during MPA 
therapy. 
 
 Figure 1.1: Pharmacodynamics of MPA in Lymphocytes. MPA blocks the enzymatic activity of 
IMPDH-2 which converts IMP into XMP via de novo pathway leading to depletion of XMP. XMP is 
required for the synthesis of GMP through GMP synthase. GMP is converted into GTP and dGTP via 
sequential rounds of phosphorylation. GTP is used in the transcription of RNA and “dGTP” in the 
replication of DNA. Therefore the synthesis of DNA and RNA are stopped, proliferation of lymphocytes is 




1.2 Rationale for the proposed research 
MPA impairs tight junctions (TJs) mediated small bowel barrier function [15] with not yet 
completely understood mechanism. TJ is a complex structure of multiple proteins that establish 
dynamic assembly between the adjacent cells of epithelial monolayer at apical region and 
selectively control paracellular movement of molecules and ions across the monolayer [16]. 
Several pathways such as protein kinase C (PKC) [33;34], phosphoinositide-3 kinase (PI3K) 
[17], myosin light chain kinase (MLCK) [18], Rho-associated protein kinase (ROCK) [19], and 
p38 mitogen-activated protein kinase (p38MAPK) [34;38] are activated in epithelial monolayer 
cells in response to various physiological and pathophysiological stimuli. The abnormal 
activation of one or more of these pathways can lead to the alteration of TJs proteins expression 
and/or distribution resulting in altered TJ assembly, increased permeability [20] and 
consequently causes diarrhea [21]. 
The present study was conducted to increase our understanding of the regulation and formation 
of TJs assembly using ChIP-o-Proteomics approach. To identify and characterize MPA-mediated 
TJs regulation, the following strategy was adopted. 
1. Establishment of differentiated and polarized Caco-2 cells monolayers as TJs model 
followed by MPA treatment. 
2. Immunoprecipitation of active and repressive chromatin followed by identification and 
quantification of DNA-binding proteins using mass spectrometry. 
3. Amplification of ChIP-DNA with promoter specific primer pairs of target genes using 
real time PCR. 
4. Characterization of genes involved in the regulation of cellular pathways and 
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 Cellular signaling pathways tightly associated with tight junction regulation and 
consequently to the leak flux diarrhea as summarized in this review. 
 Altered expression and/or localization of TJ proteins disturb TJs assembly and influence 
its ability to perform barrier function. 
 Several cytokine, bacterial pathogen and immunosuppressant trigger common MLCK 
pathway to increase the TJ permeability. 
 Bacterial toxins and/or oxidative stress trigger PKC dependent TJ permeability. 
 MLCK, p38MPAK and PI3K pathways represent the principal forces behind tight 





Intact and dynamic intercellular tight junctions (TJs) are crucial structural components that 
maintain epithelial barrier function and protect human body against interfering toxic and 
infectious agents. Inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and 
Crohn‟s disease (CrD) lead to increased loss of solutes and electrolytes resulting in leak flux 
diarrhea (LFD). LFD is backed by epithelial barrier dysfunction due to the altered regulation of 
TJ assembly through the disease mediated stimuli. Tight junctions receive intracellular signals 
and convert them to regulate their assembly and function. Most debated mechanism to increased 
TJ permeability are a) altered MLC-2 dependent F-actin cytoskeleton through myosin light chain 
kinase (MLCK); b) cdx-2 and src dependent increase of claudin-2 and redistribution of claudin-1 
through P13K; c) decreased expression of pore-sealing claudin-4 through P38MAPK. Moreover, 
Protein kinase C (PKC) and protein phosphatases regulate TJ assembly via altered 
phosphorylation and dephosphorylation of occludin protein. This review describes the pathways 
that are involved in the regulation of TJs assembly via leak-flux mechanisms that consequently 
leads to leak flux diarrhea. 




Gastrointestinal (GI) tract has the tremendous capacity to absorb electrolytes and water from the 
gut under normal condition where daily 8-9 liters of fluid are standing and only 100-200 ml is 
eliminated with waste (stool) [21]. Altered movement of electrolytes and water molecules and 
change in osmotic gradient is the hall mark of diarrhea [21] causing severe dehydration if not 
treated. Diarrhea is a common observation in many GI tract disturbances [22]. It has been 
estimated that within 18 months, an average individual in an industrialized country has at least 
one incident of acute diarrhea [23]. 
Mechanistically diarrhea can be divided into five different types, (i): motility disorder-dependent 
diarrhea: If the food particles moves too quickly and there are not sufficient time to absorb 
sufficient nutrients and water. This hypermotility diarrhea is caused by an excessive amount of 
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coarse foods or highly seasoned irritating food. In contrast, prolonged presence of the food 
particles in the bowel lumen causes bacterial overgrowth leading to  hypomotility  diarrhea [24] 
which is normally observed together with pancreatic insufficiency or bile-salt malabsorption. (ii) 
Osmotic diarrhea: Lactase deficiency and laxative abuse result in the accumulation of non-
absorbable water-soluble substances or poorly absorbed substances (e.g., lactulose, hexitols, 
sorbitol, and mannitol) in the small intestine that can draw water from the body into the bowel 
leading to osmotic diarrhea [24-26].  (iii) Malabsorptive diarrhea:  It is caused by insufficient 
absorption  of food nutrients (e.g glucose, galactose) across the GI tract [24]. Mutation in the 
Na+/glucose cotransporter (SGLT1) gene [27] and infection of the ubiquitous intestinal parasites 
Giardia [28] are mostly responsible for this malabsorption. (iv) Secretory diarrhea: It is due to 




) [29]. Different types of bacterial toxins 
such as; enterotoxins produced by E. coli [24] can activate such diarrheal condition. (v) Leak 
flux diarrhea (LFD): In this type of diarrhea, epithelial monolayer permeability is increased due 
to the altered TJ that allows solutes and fluid to flow back from circulation into the gut lumen 
[30;31]. Dysregulated paracellular permeability due to uncontrolled paracellular movement 
impedes normal physiological epithelial function [32]. Patients with GI tract disturbances mostly 
suffer from inflammation-induced leak-flux diarrhea [33]: Mechanistic studies of different types 
of GI tract disorders such as IBD (CrD, UC) show a key role of TJ-dependent altered 
permeability of epithelial monolayers [34] in disease progression.   
TJs are multiprotein complexes with dynamic structures at the apical region between two 
adjacent differentiated and polarized cells of epithelial monolayer that form the lining of the gut 
and many other organs of the human body [35]. TJs seal the paracellular space and act as a 
selectively permeable barrier that allow absorption of electrolytes, solutes and solvents 
molecules across the epithelial monolayer from the intestinal lumen into the circulation thus 
provides effective defense by preventing translocation of intraluminal toxin, antigen and gut 
flora (Figure 2.1) [36]. Intercellular part of TJ consists of four different types of transmembrane 
proteins families: claudins [35], occludin [37], junctional adhesion molecules (JAMs)[38] and 
tricellulin [39]. In fact, paracellular space is sealed by the interaction of protruding extracellular 
domain of these proteins between adjacent cells. These interactions can either be in cis or trans 
form and may be hemophilic or heterophilic [36]. Cytoplasmic or intracellular domain of these 
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proteins interact with various types of adaptors, scaffolds and signaling proteins to mechanically 
link and anchor the TJ with the actin cytoskeleton [40].  
 
Figure 2.1: TJs present at the apical-lateral region and control paracellular movements 
across epithelial monolayer. Paracellular movement is associated with selective movement of 
electrolytes, nutrients and water molecules between intercellular spaces of adjacent epithelial cells. TJ 
structural proteins are regulated by means of kinases, phosphatases through different cellular signaling 
pathways, resulting alteration of TJ assembly and increased paracellular movements across epithelial 
monolayer. Green arrows indicate normal pathway and red arrows altered pathways. 
The dynamic function of TJ is modulated either through direct regulations of TJ proteins or 
indirectly through changes in cytoskeleton of cells by means of kinases[41;42], phosphatases 
[43;44] and other signaling molecules [36].  In vitro [45] and in vivo [46] studies commonly 
employ transepithelial electrical resistance (TEER) and paracellular flux of macromolecules such 
as mannitol or dextran [47] to determine the TJ integrity. The present review will focus on TJ 
regulations and signaling pathways that mediate TJ through leak-flux mechanisms i.e., by 
increased epithelial permeability resulting diarrhea in different human diseases. 
2.3 Mechanisms of Leak-Flux diarrhea 
Inflammatory bowel diseases such as UC and CrD lead to an increased loss of solutes and 
electrolytes that results in leak flux diarrhea associated with epithelial barrier dysfunction due to 
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the altered regulation of TJ assembly  [34]. Brief accounts of different cellular pathways that are 
involved in this phenomenon are given below. 
2.3.1 Myosin Light Chain Kinase (MLCK) Pathway 
MLCK is a serine/threonine kinase that alters TJ assembly and increases paracellular movement 
through the contraction of F-actin base cytoskeleton via phosphorylated MLC-2. MLCK 
phosphorylates MLC-2 at serine-19 and this phosphorylation is correlated with myosin ATPase 
activity that favours contractile movement of myosin against actin and produce contraction in 
cytoskeleton of the cells [48] which consequently reorganize the TJ assembly. Myosin light 
chain phosphorylation (MLCP) reverses this reaction by dephosphorylating MLC-2 that helps to 
decrease tension within the cell‟ s cytoskeleton [49]. Increased expression and activity of MLCK 
and phosphorylation of MLC-2 are observed in the biopsy specimen of ileal and colonic epithelia 
of IBD patients positively correlated with the degree of active inflammation [50]. MLCK 
pathway is the major mechanism of LFD and is linked to several exogenous and endogenous 
factors.   
Several cytokines are involved in higher TJ permeability through MLCK pathways like elevated 
TNFα level that plays a critical role in IBD pathogenesis [51]. TNFα induces barrier dysfunction 
in intestinal epithelial monolayer [52] through MLCK mediated phosphorylation of MLC-2 that 
reorganizes perijunctional F-actin, redistributes occludin and ZO-1, and increases  TJ 
permeability [53]. Occludin is one of the important components of TJ that contribute to barrier 
function [54;55]. In vitro studies suggest that the loss of occludin from TJ through endocytosis 
results in barrier loss [56;57]. In vivo model study revealed that TNF-induced MLCK activation 
triggers caveolin-1 (principal component of caveolae membranes and involved in receptor-
independent endocytosis) dependent endocytosis of occludin that effect TJ assembly and 
function [18]. Pharmalogical inhibition of endocytosis (by dynasore/MβCD) or caveloin-1 
knockout prevents TNF-induced occludin internalization, TJ barrier loss and water secretion. 
While overexpression of occludin limited the barrier loss and consequently prevented water 
secretion [18]. In vivo studies have shown that anti-CD3 mAB injection activated T-cell 
systemically that resulted transient watery diarrhea mediated by TNF [58]. T-cell induced-TNF 












impair electrolyte absorption that contributes to intestinal fluid losses in immune-mediated bowel 
disorder patients [59]. Enterocytes from jejunum of anti-CD3 mice reveal disruption of the TJ 
and visible perijunctional cytoskeletal condensation. Genetically knockout MLCK in vivo model 
or pharmacological inhibiting MLCK significantly reveres these symptoms [60]. Still another 
cytokine, Lymphotoxin-like inducible protein that competes with glycoprotein D for herples 
virus entry on T cell (LIGHT) is a core member of TNF family and its expression is considerably 
increased in the mucosal biopsy specimen from active IBD patients [61]. LIGHT induces LTβR-
dependent activation of MLCK and MLC-2, which in turn stimulates endocytosis of occludin 
through caveolar pathway [57]. The Inhibition of MLCK (with membrane-permeant inhibitor of 
MLCK (PIK)) or caveolar endocytosis reversed the cytokine (TNF-α, IFN-γ, LIGHT) induced 
permeability in in vitro studies and TNF-dependent diarrhea was corrected in in vivo mouse 
model [57;62;63].  
Moreover, recent reports showed that immunosuppressive drug, mycophenolic acid (MPA) 
exposure increased the TJs permeability and impaired TJ proteins via MLCK/MLC-2 pathway in 
Caco-2 cells monolayer that may be a possible mechanism of diarrhea in organ transplanted 
patients taking MPA as an immunosuppressant to prevent graft rejection [64]. 
2.3.2 Certain bacterial pathogens exploit MLCK Pathway to disturb TJ assemblage.  
Enteropathogenic Escherichia coli (EPEC) is an extracellular attaching and effacing (A/E) 
pathogen that adheres to the surface of epithelial host cells and produce characteristics lesions 
[65]. EPEC uses a type-three secretion system (T3SS) to transfer over 20 secreted bacterial 
effector molecules [65] (such as EspG, EspF) to the host cell via a molecular syringe [66]. These 
effector molecules are known to exploit the MLCK pathway to trigger a broad range of cellular 
events that ultimately cause alteration in TJ assembly [47]. Among these effector molecules, 






Figure 2.2: Schematic representation of TJ regulation via PI3K and MLCK pathways activated by 
MPA, proinflammatory cytokines and Enteropathogenic E. coli (EPEC). The outermost portion of 
the figure indicates activators of PI3K, STAT6 and MLCK pathways that lead to increase permeability of 
TJ. A. EPEC injects effector proteins (EspF, EspG) into the cytoplasm of host cells (epithelial cells) via 





and redistributes of occludin from TJ assembly.  EspG inactivates microtubules and releases GEF-H1 
factor. GEF-H1 activates RhoA that in turn inactivates MYPT1, consequently activated (phosphorylated) 
MLC increases in the cytoplasm. Activated-MLC triggers F-actin based cytoskeleton, resulting 
contraction of F-actin filaments and redistribution of TJ proteins (occludin & ZO-1). B. Proinflammatory 
cytokines IL-13 and IL-6 increase expression of leaky protein (claudin-2) via STAT6 and PI3K pathways.  
nucleotide exchange factor (GEF-H1). However similar events are not observed in the epithelial 
cell infected with EPEC-mutant strain EspG1/2 
-/-
 [67]. GEF-H1 activates RhoA upon releases 
from microtubules [68] and activated-RhoA inactivates MYPT1 via Rho-associated kinase 
(ROCK) [69;70], resulting increased phosphorylated MLC  [71]. Thus infection of epithelial 
cells by EPEC stimulates the phosphorylation of MLC20 via MLCK, resulting in the contraction 
of F-actin base cytoskeleton [72] and finally decreased TEER and increased paracellular 
permeability of epithelial cell monolayer [73]. ZO-1 serves as an important linker molecule 
between the perijunctional actin and transmembrane proteins of TJ assembly, annular contraction 
in actin based cytoskeleton can dynamically affect paracellular permeability [74]. Interaction 
between transmembrane proteins (occludin, claudin-1) and peripheral membrane protein (ZO-1) 
of TJ, and restricted localization of these proteins in TJ assembly lost in the EPEC-infected T84 
cells [75]. EPEC-infected mice also significantly decrease barrier function at early post infection 
in epithelial tissue of ileum and colon along with EspF-dependent redistribution of occludin in TJ 
assembly in these tissues [76]. ML-9, an inhibitor of MLCK, prevents EPEC-induced increase in 
T84 TJ permeability and partially restores TEER [77;78]. The partially restored TEER by ML-9 
suggests the involvement of supplementary mechanisms, such as disorder of occludin from TJ 
assembly. EPEC-infection alters the localization (from TJ-associated domain to an intracellular 
compartment) of occludin and dephosphorylates occludin in T84 cells [79]. EspF (206 aa 
protein) is translocated into the host cells via T3SS and decrease TEER, increase permeability 
and redistribute occludin from TJ assembly in dose-dependent fashion [80]. Phosphorylation of 
occludin is obligatory for its localization to the TJ complex [81]. Gentamicin treatment of EPEC-
infected monolayer (T84) cells results in normal localization and phosphorylation of occludin in 
TJ assembly as compared to non-pathogenic E. coli K-12 infected monolayer. Calyculin A, an 
inhibitor of protein phosphatase 1 (PP1) and protein phosphatases 2A (PP2A) that 
dephosphorylate occludin at serine and threonine residues, completely prevents the dissociation 
of occludin from TJ and decrease in TEER (Figure 2.2 A) [79].  
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2.3.3 Phosphoinositide 3 kinases (PI3K) pathway  
This pathway is again linked to the elevated level of cytokines that play a key role in TJ 
permeability. Elevated Interleukin 6 (IL-6) is observed in the serum and tissue specimens of 
active IBD patients  [82] and correlate with the severity of disease [83;84]. IL-6 increases the 
cation-selective epithelial TJ permeability through increased expression of leaky protein, 
claudin-2. IL-6 enhances transcriptional factor activity of cdx-2 via MEK/ERK and PI3K/ERK 
dependent pathways. Activated cdx-2 binds to the cdx-2 binding site in the promoter region of 
claudin-2 and increases its transcription. Increased claudin-2 protein participates in pore-
formation and consequently increases TJ permeability. IL-6 induced increase expression of 
claudin-2 can be inhibited by blocking MEK/ERK and PI3K/Akt pathways through their specific 
inhibitors U0126 and LY294002 respectively (Figure 2.2 B) [85]. An eastern medicine 
Berberine, prevents TNFα-induced upregulation of claudin-2 and disassembly of claudin-1 via 
PI3K/AKT and tyrosine kinase src, in vitro and in vivo models [86].  
2.3.4 Signal Transducer and Activator of Transcription (STAT) Pathway 
Signal Transducer and Activator of Transcription play an important role in active transcription of 
many interleukin proteins. IL-13, produced by CD1-reactive NKT cells, has a significant role in 
the regulation of inflammation and induction of epithelial monolayer barrier disturbance in UC 
[87;88]. IL-13 binds to its receptors (IL-13Rα1/IL-4Rα) and trigger signal cascade that induce 
phosphorylation of STAT6 in colonic cell lines  that in turn increases the expression of claudin-2 
(pore-forming claudin of TJ) [88;89]. Following phosphorylation, STAT6 dimerizes and 
translocates to the nucleus to activate transcription (Figure 2.2 B) [90]. Biopsy specimens of the 
UC patient show increase expression of claudin-2 protein, while STAT6-deficient mice showed 
decreased expression of claudin-2 [88;89].  
2.3.5 P38MAPK pathway 
P38MAPK pathway closely interconnected with MLCK pathway through phosphorylation 
cascades. CrD patient shows elevated level of interleukin-1 β (IL-1β, a proinflammatory 
cytokine), in their colonic mucosa and the severity of intestinal inflammation is directly 
correlated to the level of IL-1β elevation [91;92]. In vitro  and in vivo studies showed IL-1β-
induce increased TJ permeability require p38 kinase-dependent activation and phosphorylation 
of activating transcription factor 2 (ATF-2). Following activation, ATF-2 translocates to the 
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nucleus and specifically binds to the promoter of MLCK and increases its activity (Figure 2.3 
A). IL-1 β-induced epithelial TJ permeability can be prevented by inhibiting p38 kinase activity 
(p38 kinase specific inhibitor, SB-203580), knocking down the ATF-2 by (siRNA) or mutating 
the binding site of ATF-2 in the promoter region of MLCK [42].    
Campylobacter jejuni (C. jejuni) is a major cause of bacterial food-borne diarrheal disease (GI 
disturbances) throughout the world [93]. C. jejuni infection induces phosphorylation of 
p38MAPK, ERK, hypophosphorylation and redistribution of occludin from TJ, redistribution of 
claudin-1, decreases expression of pore-sealing claudin-4 and rapid activation of NF-кB and AP-
1 in epithelial cells [94-96]. Lipopolysaccharide (LPS)-treated Caco-2 cells showed TJ damage 
by decreasing expression of occludin and ZO-1 via MAPK/ERK pathway. However, 
Somatostatin pretreatment decreases LPS-induced mRNA level of somatostatin receptor 5, 
phosphorylation of ERK1/2, blocks MAPK/ERK pathway and ameliorates LPS-dependent TJ 
damage [97]. EGF pretreatment prevents disruption of claudin-4 and translocation of E. coli C25, 
reduces jejunal colonization and distribution of C. jejuni to the liver and spleen of chicks [94].  
2.3.6 Protein kinase C (PKC) pathway 
PKC belong to serine/threonine specific kinases that are involved in the regulation of barrier 
function of epithelial and endothelial cells [98]. So far 12 different isozymes of PKC have been 
reported that are divided into three subfamilies namely; conventional PKC (cPKC α, β1, β2, γ) 
that are activated in a Ca
++
 and DAG dependent manner, novel PKC (nPKC δ, ε, θ, µ) requires 
only DAG for activation and atypical PKC (aPKC λ, δ) activated without Ca
++
 and DAG [47;98].   
Phosphorylation of occludin at serine, threonine and tyrosine residues play an important role in 
TJ assembly. Normal epithelial monolayer shows hyper phosphorylation [99] of occludin at 
serine [100]  & threonine  residues [101;102], most likely phosphorylated by different isoforms 
(i.e., λ, δ) of atypical protein kinase C (PKC) that are present close to TJ assembly [103]. 
Occludin loss interaction with anchoring proteins i.e., ZO-1, -2, -3, after phosphorylation at 
tyrosine residue (Figure 2.3 B) [104]. Dephosphorylation of occludin at the same residues is 
reported to be implicated in disrupted TJ under different external stimuli (Ca++ depletion [81], 
phorbol esters [105] and EPEC infection [79]). PP2A and PP1 directly interact with the C-
terminal tail of occludin and negatively regulate the assembly by dephosphorylating it at 
threonine and serine residue respectively [106]. Inhibition of PP2A or PP1 activity through either 
15 
 
by antisense oligonucleotide, siRNA or specific inhibitors (okadaic acid, fostriecin, calyculin-A) 
reverse these effects [107]. In addition, oxidative stress increases TJ permeability through 
kinases that phosphorylate tyrosine residue in TJ proteins (ZO-1 and occludin) [108]. Disruption 
of TJ assembly by oxidative stress is observed to be mediated by activation of c-Src and PI3K in 
the Caco-2 cells [109;110].  
Ingestion of gluten-containing diets (wheat, rye, barely) can activates inappropriate immune 
response which leads to the drastic alteration of small intestinal epithelial architecture and 
consequently enhanced epithelial permeability in celiac disease [111]. Endoscopic biopsy 
specimens showed an upregulation of pore-forming claudin-2 and -15 and simultaneous down-
regulation of tightening TJ proteins (occludin and pore-sealing claudin-3, -5, -7) in patients 
receiving gluten-containing diets as compared to the healthy controls [44]. In celiac disease, 
paracellular leakage occurred via altered subcellular distribution of Par-3 and anatypical PKC 
Isotype-Specific Interacting Partner, whereas TJ structural proteins also exhibit changed 
expression. A celiac disease specimen displays an enhanced basolateral distribution of Par-3 and 
increased expression of PP-1 in epithelial cryptic cells which dephosphorylates the occludin. Par-
3 moves to apical region of the cell and contributes to the organization of primordial junctions to 
belt-like TJs during polarization of the epithelial cells [112].  
PKCα  and PKCβ  activation  pathway is triggered by Clostridium difficile (C. difficile) that 
releases two types of exotoxins called toxin A (TcdA) and toxin B (TcdB [113] in the large 
bowel [114]. These toxins bind to gp96 [21] and chondroitin sulfate proteoglycan 4 [115] in 
epithelial cells respectively and translocate it into the cytosol. This translocation activates  PKCα 
[116] and PKCβ  but inactivate Rho proteins (Rho, Rac, Cdc42) via transfer of a sugar moiety 
using UDP-glucose as a co-substrate [114]. All these changes result in alteration of actinomycin 
ring [47] and translocation of adaptor protein (ZO-1) from TJ assembly (Figure 2.3 B) [116]. 
These toxin based adverse effects can be inhibited by PKCα/β antagonist  (myristoylated 
PKCα/β peptide) that block RhoA glucosylation [116].   
Vibrio cholarae (V. cholarae) enters with contaminated water into the small intestine of human 
that causes profuse diarrhea and leading to severe dehydration and delayed treatment can result 
death of the infected patients [117]. Heamgglutinin/protease (HA/P), RTX and zonula occludin 
toxin (ZOT) are toxins produced by V. cholerae and involved in the alteration of TJ assembly 
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[21] via different mechanisms. HA/P, an extracellular protease, cleaves integral membrane 
protein (occludin) and rearranged ZO-1, that are involved in the regulation of TJ assembly [118]. 
RTX crosslink the actin base cytoskeleton of the cells changing cell morphology (from columnar 
to round shape), resulting significantly decrease in TEER and increase in permeability (measured 
by FITC-dextran 3000) [119]. While ZOT, 44.8 KDa protein, is involved in the reversible 
regulation of TJ assembly via PKC dependent pathway [40]. ZOT is non-functional in its phage 
associated form [21]. It is cleaved into an active 12 KDa peptide [120]. Structure-function 
analysis reveals that amino acids (aa) located between 288-293; are biologically active portion of 
the ZOT at N-terminal and consist of 6 aa „FCIGRL‟ called PAR2 activity motif [121]. Active 
peptide of ZOT binds to the apical receptor, zonulin [122] and internalized into cytoplasm [123] 
where PAR2 activity motif increase PKC-dependent phosphorylation of ZO-1 and myosin C1 
(Figure 2.3 B) [40]. PAR2 Activity motif of ZOT increases PKC-dependent phosphorylation of 
serine and threonine residues present in protein binding domains of ZO-1 and alter the 
interaction of ZO-1-claudins and ZO-1-occludin resulting redistribution of occludin and ZO-1 in 
TJ [40]. ZOT also increase phosphorylation of myosin C1 and diminish myosin C1-ZO1 
interaction [124] consequently increase TJ permeability. ZO-1 (225 KDa) is a phosphoprotein 
that consists of several protein binding domains such as; PKZ domains, src homology (SH) 3 
domain, GUK domain [125] etc. These domains play a key role in the organization of TJ 
assembly complex [124;126]. Claudin family members interact with ZO-1 via PDZ domain to 
anchor with intracellular cytoskeleton [125] while occludin is bound to ZO-1 via unique 5 
(present between SH3 and GUK domains) domain [127]. Finally ZO-1 bound integral membrane 
proteins of TJ (claudins and occludin) are linked to actin based cytoskeleton [126] via the C-




       
Figure 2.3: Strategies used by proinflammatory cytokine and bacterial toxins to regulate TJ via 
p38MAPK and PKC pathways. A. Transmembrane proteins (occludin, claudins) are anchored to F-actin 
based cytoskeleton via adaptor protein (ZO-1). IL-1β activates P38MAPK-dependent MLCK, which acts 
on TJ-associated F-actin filaments via MLC-2 phosphorylation. Phosphorylated MLC-2 triggers myosin 
contraction that resultant redistribution of ZO-1 and its linked proteins of TJ consequently disrupt TJ 
assembly.  B. Bacterial toxins (tcdA, tcdB, ZOT) bind and internalize by their relevant apical receptors of 
epithelial cells, activate PKC pathway. Disruption of TJ by PKC pathway occur either directly by 





inactivation of Rho GTPases consequently contraction of F-actin cytoskeleton and redistribution of TJ 
protein. 
2.3.7 JunD pathway 
JunD is overexpressed in inflammatory intestinal mucosa of pediatric patients with IBD [128] 
and represses transcription and translation of TJ protein (ZO-1) in intestinal epithelial cells, in 
turn causing an increase in epithelial paracellular permeability [129]. Transcription is inhibited 
through direct binding with cAMP response element-binding protein (CREB)-binding site in the 
promoter region of ZO-1, while translation is inhibited by promoting the interaction of 3‟-UTR 
of ZO-1 mRNA with RNA-binding protein TIAR (translation repressor) [130] in epithelial cells 
[129]. JunD-induced transcription and translation of ZO-1 was shown to be prevented by either 
mutating CREB-binding site in the promoter region of ZO-1 or by reducing TIAR expression 
through siRNA [129].   
2.3.8 Salmonella and TJ regulation  
Contaminated food and water are the major sources by which Salmonella gain entry into the 
human GI tract, causing gastroenteritis and infections and resulting significant morbidity and 
mortality worldwide [131]. Salmonella disrupts TJ assembly either directly via TJ structure 
protein regulation or indirectly though actin regulation. Infection of Salmonella AvrA-deficient 
strain disrupts TJ assembly via decrease expression of occludin-1, ZO-1 and claudin-1 in 
intestinal epithelial cells as compared to AvrA-sufficient strain [132]. Sodium butyrate enhance 
intestinal barrier function via specificity protein 1 (SP-1) transcription factor dependent increase 
expression of claudin-1 [133].  
T3SS, encoded by Salmonella Pathogenicity Island-1 (SPI-1) [134;135], is activated upon 
contact with the host and injects around 12 effectors into the cytoplasm of host cells that modify 
cell signaling pathways of host cells [136;137]. Among these 12 SPI-1-secreted effectors, only 
SopB, SopE, SopE2 and Sip A disrupt Rho-dependent TJ assembly by redistributing ZO-1 and 
occludin in Caco-2/TC7 cell [131]. Comparing to wild type, different types of mutant strains of 
Salmonella (ΔsopB, ΔsopE/E2, ΔsipA, or ΔsipA/sopB, ΔsopB/E/E2 and ΔsipA/sopE/E2) were 
unable to disrupt F-actin based cytoskeleton, altered distribution of ZO-1 and occludin and 
increase permeability of polarized epithelial monolayer (Caco-2/TC7) [138]. Inhibition of 
protein geranylgeranylation, which is critical for the function of a number of proteins such as 
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RhoA and Rac [139],  prevents TJ disruption by Salmonella [138].  Rho family GTPases (Rho, 
Cdc42, Rac) are key regulators of disrupting TJ structure and functions [140] via actin base 
cytoskeleton. Both SopE and SopE2 act as GEFs for activating Cdc42 and Rac1 [141;142], while 
SopB (a potent inositol phosphatase) stimulates Cdx42-dependent reorganization of F-actin 
based cytoskeleton via phosphoinositide fluxes [143]. SipA binds to F-actin and stabilizing F-
actin filaments as well as enhancing the activity of actin-bundling proteins (T-plastin)[144]. 
2.3.9 EGFR/JNK pathway  
Salmonella increases c-Jun dependent expression of TJ leaky protein (claudin-2) via EGFR/JNK 
pathway for invasion as learned from both in in vitro (HT29C19A) and in vive (C57BL6 mice) 
models. Inhibition of EGFR, an upstream regulator of JNK, with Gefitinib (EGFR inhibitor) or 
JNK with SP600125 (JNK inhibitor) block the Salmonella-induced expression of claudin-2. 
EGFR/JNK inhibitors could also block the increase expression of c-Jun (downstream target of 
JNK) in Salmonella infected epithelial cells [145] suggesting claudin-2, as a potential therapeutic 
target to prevent bacterial invasion. 
2.3.10 Clostridium perfringens enterotoxin (CPE) and TJ regulation 
C. perfringens causes GI infections by producing up to 16 different types of toxins, including 
enterotoxin (Clostridium perfringens enterotoxin (CPE) [146]). CPE has a C-terminal binding 
domain and N-terminal biologically active domain [147;148]. Following binding to the cell 
surface, CPE remains associated with the plasma membrane and increases membrane 
permeability [149]. CPE-induced increased permeability pore include a Ca
++
 influx that trigger 
apoptotic/cell death pathways [150;151]. It also physically interacts with claudin-3 and -4 [152] , 
and claudin-8, -14 [153] upon contact with CPE-sensitive enterocyte. Aspargine-149, present at 
the extracellular loop-2 in claudin-3, -4, -8 and -14 [154;155] plays an important role between 
the interaction of claudins and CPE [153;156]. These claudins work as CPE receptors [153] and 
therefore CPE interaction selectively removes claudin-4 from TJ with its concomitant 
degradation [156]. This morphological change of claudins in TJ correlates temporally with 
decreased TER and increased paracellular flux [157]. The colonic specimen of IBD patient 
shows downregulation of claudin-4 (pore-sealing protein of TJ) and upregulation of claudin-2 
(pore-forming protein of TJ) [88;158]. This regulation of claudins-2 and 4, respectively 
contribute to defective barrier function of TJ that control paracellular movements across 
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epithelial monolayer, resulting leak-flux diarrhea in IBDs collagenous colitis patients [158]. On 
the other hand, whey protein concentrate 1 (WPC1) a natural source of TGFβ in human nutrition 
TGFβ provides natural barrier protection by reversing the downregulation of claudin-4 [159].  
2.3.11 Concluding remarks 
Compromised TJ integrity by modulation of signaling pathways is a key feature in numerous 
human diseases. Significant progress has been made over the past decades to better understand 
the molecular mechanisms of complex signaling pathways that are involved in the TJ regulation. 
However, an enormous amount of work still remains to be done to reconcile information in 
studying signaling pathways using in vitro and in vivo disease models. Particularly a systematic 
effort is required to exploit the true potential of emerging technologies like epigenetics, 
peptidomics and proteomics to identify novel signaling molecules and to explore better 
therapeutic intervention for the TJ assembly related human abnormalities.  
2.4 Acknowledgements 
The author is grateful for continued support of his mentor, and acknowledges supports from 
faculty member, department of Biotechnology and Genetic Engineering, and administrative staff, 
Kohat University of Science and Technology, Pakistan. We sincerely thanks to the researchers 
whose work are cited in this article and apologize to those whose work we could have cited, but 
did not due to space restrictions. The author is awarded PhD scholarship by Higher Education 








3 Transcriptional Regulators of Claudins in Epithelial Tight Junctions 
Niamat Khan
1,2 
and Abdul R. Asif
1* 
1
Institute for Clinical Chemistry / UMG-Laboratories, University Medical Centre, Robert-Koch-
Str. 40, 37075, Goettingen, Germany. 
2
Department of Biotechnology & Genetic Engineering, 
Kohat University of Science and Technology, Kohat 26000, KPK, Pakistan 
* Author to whom correspondence should be addressed;  
 




Human gastrointestinal tract is covered by a monolayer of specialized epithelial cells that 
constitute a protective barrier surface to external toxic and infectious agents along with 
metabolic and digestive functions. Intercellular junctions among epithelial cells, such as 
desmosomes, adheren, gap and tight junctions (TJs) not only provide mechanical integrity, but 
also limit movement of molecules across the monolayer. TJ is a complex structure composed of 
approximately 35 different proteins that interact with each other at the apical side of two adjacent 
epithelial cells. Claudin family proteins are important members of TJ with so far 24 known 
isoforms in different species. Claudins are structural proteins of TJ that help to control the 
paracellular movement by forming fence and barrier across the epithelial monolayer. Altered 
function of claudins is implicated in different form of cancers, inflammatory bowel diseases 
(IBDs) and leaky diarrhea.  Based on their significant role in the molecular architecture of TJ, 
diversity and disease association, further understanding about claudin family proteins and their 
genetic/epigenetic regulators are indispensable. 
Key words: Claudins, Promoter Binding, Epithelial Tight Junction, Transcription Factors, 
Inflammation 
3.2 Introduction 
Epithelial monolayer (EM) is the largest body tissue lining many organs in the human body. In 
the intestine, EM provides protection to the internal body from toxic and infectious agents while 
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at the same time facilitates absorption of digested food and water from the gut. Epithelial 
monolayer integrity and paracellular  transport are the important features that can be protected 
and maintained with the help of epithelial barrier function [160]. Epithelial cells are connected 
with each other by four types of junctions i.e., desmosomes, gap junctions, adheren junctions and 
TJs [161-163]. Tight junctions are impermeable and control the movement of molecules and ions 
via a paracellular pathway. Until recently, tight junction functions were categorized as “fence” as 
they separate the apical and basolateral cell surface domain defining cell polarity or a “barrier” 
due to their control over solutes and liquid flow through the paracellular space between the 
epithelial cells [164-167]. However TJs are not restricted to the fence and barrier function, but 
have been defined to participate in signal transduction processes, gene expression, cell 
proliferation and differentiation [168-170]. Various unidentified external and internal regulators 
impair the normal function of TJs causing loss of water and solute in the passive manner that 
leads to leak-flux watery diarrhea. The unwanted invasion of noxious luminal antigens prolongs 
the existence of mucosal inflammatory processes. [171].  
Tight junction (TJ) is a complex structure constituting of growing numbers of components, 
including integral membrane proteins (claudins, occludin, junctional adhesion molecules 
“JAMs”) and peripheral membrane proteins. The peripheral membrane proteins includes  (1) 
scaffold PDZ (Post synaptic density protein (PSD95), Drosophila disc large tumor suppressor 
(Dlg1), and Zonula occludens-1 protein (ZO-1), multi-PDZ domain protein-1 (MUPP1), 
Membrane-associated guanylate kinase (MAGI-1); (2) no-PDZ expressing proteins such as 
cingulin, symplekin, atypical protein kinase C, Ras-related protein Rab-3B (Rab3b), Ras-related 
protein Rab-13 (Rab13), Phosphatase and tensin homolog (PTEN),  7H6 antigen;  (3) cell 
polarity molecules ASIP/PAR-3, Partitioning defective 6 homolog alpha (PAR-6), PALS1-
associated TJ protein (PATJ) [172;173]. Besides these proteins, tricellulin protein has recently 
been identified at the epithelial cell junctions with involvement in the barrier function [174].    
Claudin family so far includes 24 reported members in different types of mammalian cells, 
among them 21 are known components of TJ in EM in the kidneys, liver, brain and intestine 
[175]. These are involved in various physiological processes such as regulation of paracellular 
permeability and conductance. Claudins are found in homo and heterotypic manner in single TJ 
[176;177]. They can be divided into two main categories; “pore-sealing” and pore forming 
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claudins. Claudin-1, -3, -4, -5, -7 and -19 are known as pore- sealing claudins and an increased 
expression of these claudin proteins lead to increased tightness of EM, increased transepithelial 
electrical resistance (TEER) and decreases solute permeability across the monolayer [178-182]. 
On the other hand, claudin-2 and -15 are considered as the “pore-forming claudins”, because of 
their ability to form paracellular anion/cation pores as well as water channels and therefore 
decrease epithelial tightness and increase solute permeability [176;183]. 
Epithelial barrier dysfunctions occur in inflammatory bowel diseases (IBDs) like crohn‟s disease 
(CD) or ulcerative colitis (UC) that contribute to leaky flux diarrhea i.e., loss of solutes and 
water in increased amount dependent upon the components of TJ proteins. Downregulation of 
pore-sealing claudins (e.g., 4, 5, and 8) while upregulation of pore-forming claudin-2 are 
observed in active Crohn‟s disease patients [184;185]. Similarly downregulation of pore-sealing 
claudin-4 is also associated to UC disease [185]. Numerous studies have reported leaky diarrhea 
in patients undergoing immunosuppressive therapy after organ transplantation [12;186-188]. 
Recently our group has reported mycophenolic acid (MPA)-mediated increased expression of 
myosin light chain kinase (MLCK) myosin light chain (MLC-2) as well as MLC-2 
phosphorylation and redistribution of ZO-1 and occludin in Caco-2 as well as in HEK-293 cells 
[189;190] as a possible mechanism of diarrhea in patients undergoing immunosuppressive 
therapy. Transcription factors (TFs) play an important role in the gene regulation at the promoter 
level either working as an activator or repressor of a specific gene. Current review will focus 
major claudins family members and their regulators, which alter claudins gene activity at 
promoter level and therefore modulate TJs structure and function. 
3.2.1  Claudin 1:  
Claudin 1 protein is a key constituent of TJs and its altered expression is reported in a variety of 
cancers, most prominently colorectal cancers [176;191-193]. Promoter region (-1160 bps to -850 
bps) of claudin-1 consists of putative binding sites for caudal-related homeobox (cdx-1, 2), 
GATA4 and T-cell factor/lymphoid enhancing factor-1 (Tcf/Lef-1) transcription factors. There is 
a direct correlation between claudin-1 and cdx-2 expression in human colon cancer patient [193]. 
Cdx-2 is a homeobox domain-containing nuclear transcription factor that plays an important role 
in intestinal development by regulating the proliferation and differentiation of intestinal cells 
[194-196], and it is expressed in all cells along the crypt villus axis. Cdx-2 transcriptional 
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activity is controlled through ERK, MAPK pathway which phosphorylates it at ser-60 position 
and resultantly reducing cdx-2 transcription activity in crypt and lower villus cells. On the other 
side, cyclin-dependent kinase 2 (CDK2) phosphorylates cdx-2 at Ser-281 which coordinate cdx-2 
polyubiquitination and degradation by the proteasome [194;197-200] 
Specificity protein 1 (Sp-1) is the first identified transcription factor of specificity 
protein/Krüppel-like factor (Sp/XKLF) family, consisting of 785 amino acids (aa)  with 
molecular weight of 100 to 110 kDa.  Sp-1´s DNA binding domain is the most conserved among 
other domains of SP family members which is consisted of Cy2His2 Zinc (Zn) fingers. 
Mutational analysis has revealed that Zn fingers 2 and 3 are essential for DNA binding activity 
[201]. Sp-1 binds to the GC-rich elements [202] that are common regulatory elements in the 
promoters of numerous genes. Sp-1 binds its individual binding sites as a multimer and is 
capable of synergic activation of promoters containing multiple binding sites [203] and regulates 
transcription by dynamically recruiting and forming complexes with many factors associated 
with transcription [204]. Normally Sp-1 has been described as a transcriptional activator but it 
can also act as a repressor [205]. Claudin-1 promoter region (-138 to -76 bp) contains Sp-1 
binding site and a mutation in this region results in a significant loss of claudin-1 transcription 
[206].  
3.2.2 Claudin 2 
Claudin-2, also known as leaky protein, forms paracellular water channels in TJs and mediates 
paracellular transport of water molecules across the EM. EM permeability is enhanced by 
increased expression of claudin-2 in TJs. It is also involved in many signaling pathways, 
including vitamin D receptor, epidermal growth factor receptor (EGFR), and c-Jun N-terminal 
kinases (JNK) signaling pathways, and contributes to inflammatory bowel disease and colon 
cancer [184;207-210]. Salmonella infection facilitates bacterial invasion across the EM by 
inducing claudin-2 expression and altering its localization in TJs which is reversible by specific 
inhibitors (EGFR (Gefitinib) & JNK (SP600125), making claudin-2 as a  potential therapeutic 
target to prevent bacterial invasion and inflammation [211]. 
Interleukin-6 (IL-6) increases TJ permeability of Caco-2 monolayer from the basal side by 
inducing caludin-2 expression. IL-6 activates the mitogen-activated protein kinases/extracellular 
signal-regulated kinases (MEK/ERK) pathway by inducing phosphorylation of ERK, and 
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phosphatidylinositol 3' -kinase (PI3K/Akt), by phosphorylating Akt, which in turn enhances cdx-
2 expression. In the claudin-2 promoter region (-1067 to -1), four cdx-2 (cdx-A, B, C, D), STAT 
and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) putative binding sites 
are identified. IL-6 induced expression of claudin-2 can be reversed by either using specific 
inhibitors of MEK/ERK and PI3K/AKT pathways (U0126 (a MEK inhibitor), LY294002 (a 
PI3K inhibitor) or site directed mutagenesis in the putative cdx-2 binding sites in the promoter 
region of claudin-2 gene [212].  
3.2.3 Claudin-3, Claudin-4, and Claudin-5  
Claudin-3 and claudin-4 both are overexpressed in ovarian cancer. A Sp-1 binding site (‑112 and 
‑74 bps) in the promoter region of claudin-3 is crucial for its activation. Claudin-3 expression is 
significantly decreased at mRNA and protein levels, by knocking down the Sp-1 with siRNA, 
indicating an essential role of Sp-1 in claudin-3 activation [213]. Claudin-4 is mainly expressed 
in the EM of colon, renal tubules, mammary gland, thyroid gland and considerably raised in their 
cancers [214]. There are two known Sp-1 binding sites (between -105 to -49 bps) in the promoter 
region of claudin-4 [215]. Caludin-5 is mostly expressed in the TJs of EM of pancreatic acinar, 
alveolar lung cells, colon, endothelial cells forming the blood-brain barrier and endonurial blood-
nerve barrier. In colonic regions, its expression is mainly involved in the paracellular sealing of 
TJs [184;216-218]. Both downregulation and redistribution of claudin-5 can alter TJs structure 
leading to barrier dysfunction in active Crohn‟s disease [184]. Forkhead box (foxO) gene family 
members are potent transcriptional activators with four known members; foxO1 (also known as 
foxO1a), foxO3 (also known as foxO3a), foxO4, and foxO6 which bind to conserved consensus 
core recognition motif TTGTTTAC [219-221]. Four pairs of putative binding sites for foxO and 
tcf–β-catenin (Tcf–β-catenin act as a stabilizer) are identified in the three regions of claudin-5 
promoter (region 1, position −2,906/−2,871; region 2, position −2,317/−2,287; region 3, position 
−1,103/−1,008). Both foxO1 and tcf–β-catenin interact with region 1 of the caludin-5 promoter 
to repress its transcription [222]. 
3.2.4 Claudin-7 
Claudins-7 is expressed prominently in the biphasic type of synovial sarcoma of adults.  E74-like 
factor 3 (ELF3) belongs to E26 transformation-specific sequence (ETS) family of transcription 
factors and binds to the Ets binding site in the promoter region (-150 bps) of claudin-7 [223]. 
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Members of ETS family are mainly involved in cell differentiation, proliferation and cell 
transformation [224]. Regulation of the target genes by ETS factors depend upon their activation 
by MAPK and their association with other cofactors [225;226]. An essential role of ELF3 is 
reported in epithelial cell differentiation [227-229] and small interference RNA (siRNA) 
treatment downregulates the claudin-7 expression validating the central role of ELF3 in claudin-
7 activation.  
3.2.5 Claudin-15 
Claudin-15 is a pore-forming protein expressed in the EM of intestine, liver and kidney tissues. 
Downregulation of claudin-15 decreases permeability of EM layer and can initiate IBD. Four 
putative binding sites (BS1-4) of transcription factor hepatocyte nuclear factor 4 alpha (hnf4α) 
are present in the (-693 to -47 bps) region of claudin-15 promoter [230]. Hnf4α is considered as 
an important regulator of EM barrier integrity and is involved in the regulation of metabolism, 
cell junction, differentiation and proliferation of liver and intestine epithelial cells [231]. Both 
animal model and IBD patients‟ biopsy studies have shown an altered expression of hnf4α 
directly influence the expression and distribution of claudin-15 [230]. 
3.2.6 Claudin 19 
The kidney is responsible for the filtration of excretory material from the blood. However, 25–
40% of filtered Na
+ 
[232], 50–60% of filtered Mg
2+ 
[233] and 30–35% of filtered Ca
2+ 
[234] are 
re-absorbed into the body by thick ascending limb, the loop of Henle. Claudin-16 and -19 play a 
main role in the regulation of Mg
2+ 
reabsorption and loss of either claudin-16 or -19 lead to 
excessive renal waste of Mg
2+ 
[235]. Four putative transcription factor (unknown, AP2, NF-E 
and Sp-1) binding sites are located between -139 and -75 in the promoter region of mouse 
claudin-19. However, only Sp-1 is described for having an important role in the expression of 
claudin-19 and a mutation in Sp-1 binding site significantly reduces the claudin-19 expression 






Table 3.1 Regulators of claudins 
TJ Proteins Regulator Promoter binding region Expression / Ref. 
Claudin-1 
 Sp-1 -138 to -76 bp ↑[206] 
cdx-2 -1160 to -850bp ↑ [193] 
Claudin-2 cdx-2 -1067 to -1bp ↑[212] 
Claudin-3 Sp-1 ‑112 to‑74bp ↑[213] 
Claudin-4 Sp-1 -105 to -49 bps ↑ [215] 
Claudin-5 FoxO1 −2,906 to −2,871 bps ↓ [222] 
Claudin-7 ELF-3 -150 bps ↑ [223] 
Claudin-15 Hnf4α -693 to -47 bps ↑ [230] 
Claudin-19 Sp-1 -139 to -75 bps ↑ [236] 
Note: arrow (↑) = upregulation, arrow (↓) = downregulation  
3.3 Conclusion: 
Tight junctions play an important role in the regulation of paracellular movement of molecules 
across the EM, impart mechanical strength, maintain the polarity of cells and prevent the passage 
of unwanted molecules and pathogens through the space between the plasma membranes of 
adjacent cells. The efficiency of the junction in preventing ion passage increases exponentially 
with the number of strands of claudins family proteins which are having important role in the 
structure as well as controlling paracellular movement across the tight junctions. Altered 
expression of claudins family proteins in TJs plays a key role in numerous abnormalities like; 
cancers, IBDs and leaky diarrhea and a better understanding of their regulatory mechanism could 
help in designing innovative therapeutic strategies. 
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4.1 Abstract 
Background : Mycophenolic acid (MPA) is an important immunosuppressive drug (ISD) 
prescribed to prevent graft rejection in the organ transplanted patients, however, its use is also 
associated with adverse side effects like sporadic gastrointestinal (GI) disturbances. Recently, we 
reported the MPA induced tight junctions (TJs) deregulation which involves MLCK/MLC-2 
pathway. Here, we investigated the global histone acetylation as well as gene-specific chromatin 
signature of several genes associated with TJs regulation in Caco-2 cells after MPA treatment. 
Results: The epigenetic analysis shows that MPA treatment increases the global histone 
acetylation levels as well as the enrichment for transcriptional active histone modification mark 
(H3K4me3) at promoter regions of p38MAPK, ATF-2, MLCK and MLC-2. In contrast, the 
promoter region of occludin was enriched for transcriptional repressive histone modification 
mark (H3K27me3) after MPA treatment. In line with the chromatin status, MPA treatment 
increased the expression of p38MAPK, ATF-2, MLCK, and MLC-2 both at transcriptional and 
translational level, while occludin expression was negatively influenced. Interestingly, the MPA 
induced gene expression changes and functional properties of Caco-2 cells could be blocked by 
the inhibition of p38MAPK using a chemical inhibitor (SB203580).  
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Conclusion: Collectively, our results highlight that MPA disrupts the structure of TJs via 
p38MAPK-dependent activation of MLCK/MLC-2 pathway that results in decreased integrity of 
Caco-2 monolayer. These results led us to suggest that p38MAPK-mediated lose integrity of 
epithelial monolayer could be the possible cause of GI disturbance (barrier dysfunction) in the 
intestine, leading to leaky style diarrhea observed in the organ-transplanted patients treated with 
MPA.  
 
Key words: Tight Junction, Permeability, MPA, Epigenetic, Promoter activity 
 
4.2 Introduction 
Mycophenolate mofetil (MMF) and enteric-coated mycophenolate-sodium (EC-MPS) are two 
commercially available formulations of immunosuppressive regimens that contain active agent 
mycophenolic acid (MPA) [237;238]. MPA inhibits the activity of inosine monophosphate 
dehydrogenase (IMPDH), a vital enzyme in the de novo synthesis of guanine nucleotide, thus 
preventing the synthesis of DNA and thereby inhibits growth and division of rapidly growing 
cells such as lymphocytes of the immune system [239]. This property makes MPA as an 
effective immunosuppressive regime to suppress the immune system in order to prevent graft 
rejection in organ transplanted patients. Though MPA is vital to suppress the immune system to 
prevent graft rejection, its use is linked to the gastrointestinal (GI) disturbances in the 
transplanted patients (for details, see review articles [240;241]). Several studies have shown that 
defect in the intestinal barrier function due to MMF or EC-MPS treatment results in increased 
permeability of intestinal mucosa (epithelial monolayer) for the solutes [237], develop leak-flux 
diarrhea in the rat model [238], and in renal and kidney transplanted patients [239;240].   
Gastrointestinal disturbances in inflammatory bowel diseases (IBD) like Crohn‟s disease and 
ulcerative colitis, and in graft versus host disease are mainly characterized by epithelial 
monolayer barrier defects which contribute to enhanced intestinal permeability [242] and 
subsequent translocation of infectious agents and/or endotoxin from gut [243;244]. Epithelial 
cells are connected with each other by four different types of junctions called desmosomes, gap-, 
adheren-, and, tight- junctions (TJs) [245-247]. TJs are complex structure of approximately 35 
30 
 
different proteins including integral membrane proteins (claudins, occludin, junctional adhesion 
molecules “JAMs”) and peripheral membrane proteins (Zonula Occludens (ZO) such as ZO-1, 
ZO-2, and ZO-3) [172;173]. TJs assist to seal the paracellular space between the adjacent cells, 
and is particularly involved in regulating barrier and fence functions [248]. In “barrier function”, 
TJs regulate the passage of ions, water, and various molecules through paracellular pathways. 
Thus aberrant barrier function can cause edema, jaundice, diarrhea and blood-borne metastasis, 
however, the cell polarity is maintained by forming a fence to prevent intermixing of molecules 
between apical and lateral membrane. It is interesting to note that the altered fence function is 
involved in cancer progression in terms of loss of cell polarity [249].  
In GI tract, TJs opening is considered as a key limiting factor of mucosal paracellular movement 
of nutrients and solutes. Growing evidences have indicated that TJs opening is modulated by the 
phosphorylation of myosin light chain 2 (MLC2), which principally depends upon the activation 
of MLC kinase (MLCK). The MLCK itself is however triggered by different types of stimuli 
such as IFN-gamma, TNF-alpha, and LIGHT (Lymphotoxin-like inducible protein that competes 
with glycoprotein D for herpes virus entry on T cells). This stimulation results in contraction of 
cytoplasmic actin filaments and redistribution of TJs anchoring protein, ZO-1 and structural 
protein, occludin in IBD (Crohn‟s disease, ulcerative disease), leaky flux diarrhea, and cholera 
(watery diarrhea) [250-254]. . Recently, it has been shown that proinflammatory cytokine (IL-
1β) induces TJs permeability in both in vitro and in vivo models through p38MAPK/ATF-2-
dependent regulation of MLCK activity [255]. p38MAPK is activated by various cellular stress 
agents ( i.e., UV irradiation, heat shock, osmotic stress, lipopolysaccharide, cytokines) [256;257] 
and is known to play a vital role in apoptosis, cytokines production, transcriptional regulation 
and cytoskeletal reorganization [258-260]. Previously, we reported that MPA alters TJs assembly 
in Caco-2 monolayer, similar to GI tract, via MLCK/MLC-2 pathway [253].  
The aim of the present study was to investigate whether MPA treatment leads to increased TJs 




4.3 Material and Methods 
4.3.1 Experimental Design  
We used Caco-2 cells as a model cell line to investigate the MPA-mediated TJs modulation via 
p38MAPK dependent MLCK/MLC-2 pathway. Towards this, we established three groups: 1. 
MPA-treated group, 2. SB+MPA-treated group, and 3. DMSO (control)-treated group of 
differentiated and polarized Caco-2 cells monolayers. Each group was treated with MPA or 
SB+MPA or DMSO for 72 hrs. Different molecular analyses (epigenetic, mRNA expression, 
protein expression, and phosphorylation status) and functional analyses (TEER and FITC-
Dextran dye flux) were performed to explore the role of p38MAPK-dependent MLCK/MLC-2 
pathway in maintaining epithelial monolayer integrity following MPA treatment. 
4.3.2 Chemicals/Reagents 
Cell culture media Dulbecco's Modified Eagle's medium (DMEM), fetal calf serum (FCS), 
phosphate buffer saline (PBS), penicillin and streptomycin were purchased from PAA 
Laboratories,Pasching, Austria. Fluorescein isothiocyanate-conjugated dextran (FITC-dextran), 4 
kDa (FD4), Trypsin, MPA, and DMSO were purchased from Sigma-Aldrich, Steiheim, 
Germany. Protease and phosphatase inhibitor cocktails were purchased from Roche, Mannheim, 
Germany. Bromophenol blue was obtained from Carl Roth, Karlsruhe, Germany. Sodium 
dodecyl sulfate (SDS) was obtained from Serva, Heidelberg, Germany. Glycerin, potassium 
ferricynaide and sodium thiosulfate were purchased from Merck, Darmstadt, Germany. Formic 
acid was purchased from BASF, Ludwigshafen, Germany. Magnesium chloride (MgCl2), M-
MLV RT enzyme, and 5X PCR buffer were from Invitrogen, Karlsruhe, Germany. 
Deoxynucleotide triphosphates (dNTPs) were from Roche, Mannheim, Germany and PCR 
primers were synthesized by Eurofins, Ebersberg, Germany. Ribonuclease (RNAase) inhibitor 
was obtained from Promega, Mannheim, Germany. The cell lysis buffer (10X) was obtained 
from Cell Signaling Technology, Danvers, MA, USA. All other chemicals used in this work 
were from the highest available purity from commercial sources unless otherwise stated. 
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4.3.3 Primer Design 
Promoter sequences were retrieved for each gene using Transcriptional Regulatory Element 
Database (TRED). Primer3 (v. 0.4.0) was used to design primers against promoter region and 
their specificity was checked by Human BLAT Search.   
4.3.4 Cell Culture 
All experiments were performed with human colon carcinoma (Caco-2) cells (Passages No. 15-
25). Caco-2 cells were purchased from DSMZ (German collection of microorganisms and cell 
culture, Braunschweig, Germany) and grown in DMEM medium supplemented with 10% FBS, 
1% Penicillin/Streptomycin, 1% non-essential amino acids. Confluent monolayers were obtained 




) and grown further for 13 days (d) post-
confluency. Medium was changed every other day after formation of confluent monolayer. Three 
groups were established i.e., MPA-treated, SB203580 (SB)+MPA-treated and DMSO treated 
(control group). Cells were washed with PBS prior to the 72 h exposure with either MPA 
(10µM) or DMSO. In case of SB (10µM) treatment, cells were incubated with SB one hour prior 
to the addition of MPA.  
4.3.5 Caco-2 monolayer integrity assays 
4.3.5.1 Determination of trans-epithelial electrical resistance (TEER) 
The intactness of paracellular pathways that control small molecules movement across Caco-2 
monolayer was examined by TEER as previously described [189;261]. Briefly, Caco-2 cells 
were seeded on polyester transwell inserts (6.5mm diameter, 0.33 cm
2
 grow surface area, 0.4 µm 
pore size; Corning Costar corporation, USA) at a density of 2 × 10
5
 cells/well. Stable TEER of 
confluent monolayer was achieved at days 13-15 after seeding. Caco-2 plated filter having 
constant TEER (≥400 Ω.cm
2
) were included in experiments. Post-confluence monolayers having 
stable TEER were treated with MPA or SB plus MPA or DMSO (control) for 72 h. TEER was 
measured at 0, 12, 24, 48 and 72 h time period using an epithelial voltammeter (EVOM2, World 
Precision Instruments) with a STX2 electrode (World Precision Instruments, FL, USA). The 
TEER values were normalized by against background resistance of a blank insert that contained 




) using the following formula: 
Resistance (TEER) = [RC-RE] X A), where RC is resistance of the cells (Ω); RE is resistance of 
the blank (Ω); A is surface area of the membrane insert (cm
2
). The results were expressed as the 
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change in TEER with respect to time-matched controls [ΔTEER (Ω.cm
2
)]. TEER values were 
calculated in three independent biological replicates each performed in duplicates. 
4.3.5.2 FITC-dextran assay (FD4) 
After 72 h of incubation with MPA or SB plus MPA or DMSO, permeability of Caco-2 
monolayers was assessed using a previously reported dye fluxes method [189;262]. Briefly, 
Caco-2 cells were grown into monolayers and treated as described above. Following MPA 
treatment, monolayers were rinsed carefully with Hank's balanced salt solution (HBSS). To 
measure paracellular permeability (apical to basolateral fluxes), HBSS containing 1 mg/mL FD4  
solution was added to the apical side for 2 h. Permeability marker flux was assessed by taking 
100 µL from the basolateral chamber after 0, 20, 40, 60, 80, 100 and 120 minutes. Fluorescent 
signal was measured using a Lambda fluoro 320 fluorescence plate reader (MWG Biotech, 
Ebersberg, Germany) using 492 nm excitation and 520 nm emission filters. Standard curve, 
generated by serial dilution of FD4, was used to determine the FD4 flux concentrations across 
the monolayer. The flux concentration, which represents the permeability of monolayer, in the 
basolateral chamber was calculated by the following formula “Papp = (ΔCA/Δt) VA]/ACL”. 
Where Papp is the apparent permeability (cm/s), ΔCA is the change of FD4 concentration, A is 
the surface area of the membrane (cm
2
), Δt is the change of time, VA is the volume of the 
abluminal medium, and CL is the initial concentration in the luminal chamber. FD4 values were 
calculated in three consecutive experiments, each performed in duplicates. 
4.3.6 RNA expression analysis 
Cells were grown for 13 d post-confluence and treated for 72 hours in 6-well plates as described 
above. Trizol (Trizol reagent; Invitrogen, USA) was used to extract total cellular RNAs from 
Caco-2 cell monolayers (MPA-treated or SB plus MPA-treated or DMSO-treated) according to 
the manufacturer‟s instructions. Briefly, Caco-2 monolayers were rinsed with ice-cold PBS and 
harvested by scraping with a rubber policeman into Trizol reagent, homogenized by inverting the 
tube twice, and RNA was extracted using chloroform/isopropanol precipitation. The precipitated 
RNA was air dried, dissolved in sterile water and stored at -80°C until analysis. RNA was 
quantified using a NanoDrop 2000C (PeqLab, Thermo Scientific). 
Reverse transcription reaction was performed using 1µg of total RNA in a 30 µL reaction 
mixture containing 1X RT-PCR buffer (10 mmol/L Tris–HCl [pH 8.3], 15 mmol/L KCl, 0.6 
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mmol/L MgCl 2 ), 0.5 µmol/L of each dNTP, 1 U/µL RNase inhibitor and 13.3 U/µL M-MLV 
RT enzyme. The RT reactions were performed in a thermocycler (Biometra, Goettingen, 
Germany) at 65°C for 5 min, 37°C for 52 min, and then inactivated by heating at 70°C for 15 
min. cDNA was stored at -80°C until use. Online Primer 3 software was used to design primers 
for the amplification of target genes by real time PCR [263] (For primers used in this study see 
table 2). 
Light Cycler instrument (Roche, Manheim, Germany) was used to amplify cDNA in a 20 µL 
reaction mixture containing 1 µL of cDNA solution, 2 µL of 10 X PCR buffer (Invitrogen, 
Darmstadt, Germany), 2 µL SYBR green, 1 µL DMSO, 0.25 µL of each primer, 2.0 mmol/L 
MgCl2, 0.2 mmol/L of each dNTP, and 0.15 U/µL PAN Script DNA polymerase (PAN Biotech, 
Aidenbach, Germany). The following conditions were set to amplify cDNA; [{denaturation: 
95°C for 5 min, one cycle}, {40 cycles, denaturation: 95°C for 30 sec, (annealing: p38MAPK 
(56°C), ATF-2 (57°C), MLCK (56°C), MLC-2 (57°C), occludin (57°C), ZO-1 (57°C) and 
GAPDH (60°C) for 30 sec), extension (72°C) for 30 sec}].   
PCR data was normalized using internal control gene (GAPDH) and comparative Ct method (2
-
ΔΔCt
) [264] was used to calculate the alteration of relative mRNA expression as a fold change 
between MPA treated and control cells. Amplified PCR product specificity was further 
confirmed by running on 1.5% agarose gel electrophoresis. Three separate experiments were 
performed with each one in triplicates.    
4.3.7 Dot Blot 
Dot blot assay was performed as described previously [265] with little modification. Briefly, 
Caco-2 cells were cultured into differentiated and polarized monolayers and treated with the 
therapeutic concentration of MPA or DMSO for 72 h. Total cell lysate was prepared by 1X lysis 
buffer (Cell Signaling) at 0h, 1 h, 12 h, 24 h, 48 h, 72 h. Proteins were quantified by Bio-Rad 
protein assay kit according to the manufacturer‟s guidelines. One cm
2
 grid was drawn by pencil 
on nitrocellulose membrane. Two µl (protein concentration 10µg/µl) of each sample was slowly 
spotted into the center of grid using narrow-mouth pipette tips. Sample spotted membranes were 
dried at RT. Non-specific binding sites were blocked by soaking sample spotted membrane in 
5% BSA in TBST for one hour at RT on a plate shaker at low speed. Each membrane was 
incubated with primary antibody (05µg/ml rabbit anti-H3K9ac -Abcam or 1:20,000 rabbit anti-
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H4K8ac -Diagenode) dissolved in 5% BSA/TBST for two hours at RT on a plate shaker at low 
speed. Following incubation with primary antibodies, each membrane was washed three times 
for 5 min and then incubated with secondary antibodies conjugated with HRP for one hour at RT 
on a plate shaker at low speed. Then the membrane was washed three times and incubated with 
ECL reagents for two minutes, covered with saran-wrap and exposed to X-ray film in the dark 
room for different time, and proceeded for autoradiography using Konica SRX-101A (Konica 
Minolta).   
4.3.8 Western blot 
Caco-2 cells were cultured into differentiated and polarized monolayers and treated as described 
above and were rinsed and collected with ice-cold PBS. Cells were lysed with lysis buffer-CS 
(50 mM Tris/HCl, pH 7.4, 1.0% Triton X-100, 5 mM EGTA, 10 mM sodium fluoride, 2 μg/mL 
leupeptin, 10 μg/mL aprotinin, 10 μg/mL bestatin, 10 μg/mL pepstatin A, 1 mM vanadate and 1 
mM PMSF). Total proteins (cleared supernatant) were separated by centrifugation from the cell 
lysate. Protein concentrations were measured using Bio-Rad protein assay kit (Bio-Rad 
Laboratories) according to the manufacturer‟s guidelines. Total protein contents were separated 
by 12.5 % SDS-PAGE and blotted onto PVDF membrane (0.45 µm pore size, Immobilon, 
Millipore, MA, USA) using Trans-Blot SD cell system (Bio-rad, Munich, Germany) for 30 min 
at 15V in a blotting buffer (192 mmol/L glycine, 20% methanol, and 25 mmol/L Tris [pH 8.3]). 
To prevent nonspecific binding sites, each membrane was blocked with 5% milk (w/v) in TBS-T 
buffer (50 mmol/L Tris–HCl [pH 7.5], 200 mmol/L NaCl, 0.05% Tween 20) for one hour at 
room temperature. Blocked membranes were washed twice in TBS-T for 5 min, then incubated 
with following antibodies:1:10,000 dilution of mouse monoclonal anti-MLCK antibody (Sigma, 
Mannheim, Germany), 1:500 dilution of a mouse monoclonal anti-MLC-2 antibody (Sigma, 
Mannheim, Germany), 1:1000 rabbit anti-phospho MLC-2 antibody (Cell Signaling, Beverly, 
USA), 1 µg/mL rabbit anti-ZO-1, 0.5 µg/mL mouse anti-occludin (Zymed, CA, USA),  1:500 
dilution of rabbit anti-H3K9ac (abcam), 1:250 dilution of H4K8ac (diagenode) or 1:5000 anti-β 
actin (Sigma, Mannheim, Germany) in 5% BSA in TBS-T for overnight at 4°C. Following 
overnight incubation with primary antibodies, membranes were washed with TBS-T buffer and 
again incubated with appropriate HRP-conjugated secondary antibodies (Bio-Rad, Munich, 
Germany), then washed with PBS and arranged for enhanced chemiluminescence detection (GE, 
Buckinghamshire, UK) according to the manufacturer's recommendation. The 
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chemiluminescence signal was captured by hyperfilm-ECL (GE, Buckinghamshire, UK) and 
visualized using Konica SRX-101A (Konica Minolta). The densities of the specified protein 
bands between MPA-treated, SB plus MPA and control samples were quantified using ImageJ 
software (v 1.48, NIH, USA). 
4.3.9 Chromatin immunoprecipitation (ChIP) 
Caco-2 cells were cultured and treated as earlier described in “cell culture”. For ChIP analysis, 
cells were fixed with formaldehyde at a final concentration of 1.0% for 30 min at room 
temperature to cross-link DNA binding proteins and DNA [266]. Cells were harvested with ice 
cold PBS and counted by Advia 120 (Siemens) and equal number of cells were lysed according 
to the manufacturer‟s instructions (Red ChIP Kit
TM
, Diagenode). Cross-linked chromatin was 
sheared into fragments of 100–1000 bps using Branson Sonifier 250 for 3 minutes using cycles 
of 30 seconds sonication and one minute on ice. One-tenth of the sample was set aside as an 
input control, and the rest was pre-cleared with protein A magnetic beads for 30 minutes at 4°C 
with agitation. Pre-cleaned chromatin was then precipitated with active histone mark antibody 
(H3K4me3, Abcam, ab8580), as well as with repressive histone mark antibody (H3K27me3, 
Millipore, 07-449) and normal IgG (One Day ChIP Kit
TM
, Diagenode) from both treated and 
untreated cells. The Chromatin-antibodies-magnetic beads complexes were washed with 1X 
ChIP washing buffer (One Day ChIP Kit
TM
, Diagenode). Proteinase K was used to degrade the 
DNA associated proteins and DNA was isolated by DNA slurry (One Day ChIP Kit
TM
, 
Diagenode) and quantified by NanoDrop (NanoDrop 2000C, peqlab, Thermo Scientific). ChIP-
precipitated genomic DNA was amplified using real time PCR (Roche, Manheim, Germany) in 
20 µL SYBR green based reaction (For  promoter based primers see details in table 2). PCR 
amplification was done under the following conditions; [{denaturation: 95°C for 2 min, one 
cycle}, {40 cycles, denaturation: 95°C for 30 sec, (annealing: p38MAPK (60°C), ATF-2 (55°C), 
MLCK (62°C), MLC-2 (62°C), occludin (54°C), ZO-1 (55°C) and GAPDH (59°C) for 30 sec), 
extension (72°C) for 30 sec}].   
4.3.10 Data Analysis 
Ct values from real time PCR were analyzed by “input percent method” [267]. Briefly, raw Ct 
value of the diluted input (1%) was adjusted to 100% by subtracting the dilution factor of 100 or 
6.644 cycles (i.e., log2 of 100). Sample raw Ct values (ΔCt) were normalized by subtracting 
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adjusted Input (Ct Input - 6.644) Ct value. And finally the “Input percent” value for each sample 
was calculated using the following formula. Input % = 100*2^(Adjusted input - Ct (IP). The 
“Input percent” value represents the enrichment of H3K4me3 and/or H3K27me3 at the promoter 
region of genes studied. Dissociation curve analysis was performed to confirm the specificity of 
each PCR product. GAPDH was used as an internal control gene.  










Forward  TTTGACTCTTTCCCCGACAC 187 
Reverse AACTGGAGACCAAAGGCAGA 
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Statistical program GraphPad (GraphPad, San Diego, CA) was used to perform statistical 
analysis. Data was analyzed by analysis of variance (ANOVA) and comparisons between control 
and MPA treatment were made using the Bonferroni posttest. Alternatively, statistical 
significance between control and treatment group were calculated using student‟s t-test. Results 
were expressed as mean ± standard error of the mean (SEM). Probability of 0.05 or less was 




4.4.1 MPA increases global histone (H3K9 and H4K8) acetylation in Caco-2 Cells. 
Acetylation of histone proteins plays an important role in the unfolding of chromatin and 
initiation of transcription. Recently it was reported that MPA treatment increases the histone 
H3/H4 global acetylation levels in CD4
+
 T cells from systemic lupus erythematosus patients 
[268].  In order to study whether MPA treatment leads to similar epigenetic changes also in 
epithelial monolayer, Caco-2 cells monolayers were treated with MPA for various time points 
and analyzed for global histone acetylation levels using dot- and Western -blot analysis. The dot 
blot results show that MPA treatment increases global acetylation of H3K9 and H4K8 in Caco-2 
cells after 72 h (Fig. 4.1A). Western blot analysis further confirmed that MPA significantly 
increases the acetylation of H3K9 and H4K8 after 72 h (Fig. 4.1 B-D). These results indicate that 
MPA treatment significantly alters the epigenetic status of Caco-2 cells. 
4.4.2 MPA treatment activates MLCK and MLC-2 while inactivates occludin at 
epigenetic level in Caco-2 cells. 
We and other investigators have reported the involvement of MLCK pathway in the regulation of 
TJs barrier function [253;269]. In light of the global increase in histone acetylation levels after 
MPA treatment, we assessed the epigenetic status at the promoter region of MLCK, MLC-2, 
occludin and ZO-1 genes, by ChIP assay in MPA treated or untreated Caco-2 monolayer cells. 
Our ChIP data showed that the transcription permissive histone modification mark (H3K4me3) 
was increased significantly at the promoter region of MLCK and MLC-2 genes, respectively (Fig. 
4.2 A & B). Concomitantly, transcription repressive mark (H3K27me3) was decreased 
significantly at the promoter region of MLCK and MLC-2 genes, respectively, as compared to 
controls (Fig. 6A & B). While promoter of occludin lost H3K4me3 mark and gained H3K27me3 
mark in the MPA treated Caco-2 cells as compared to control cells, indicating the transcriptional 
silencing of occludin after MPA treatment (Fig. 4.2 C). However, the promoter region of ZO-1 
showed no significant changes in H3K4me3 and H3K27me3 levels between MPA-treated cells 
and control (Fig. 4.2 D).  
To confirm the influence of MPA on the epigenetic activation of MLCK and MLC-2 genes, 
transcriptional and translational expression was analyzed using quantitative PCR and 
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immunoblotting, respectively. In line with the earlier reports [253;270], MPA treatment 
significantly increased the expression of MLCK and MLC-2 both at transcriptional and protein 
level (Fig. 4.2 E-G). Further we analyzed the expression of occludin to confirm the epigenetic 
data at mRNA and protein level and found significant decrease at protein and mRNA expression 
(Fig. 4E-G). In contrast, we did not observe any significant difference in ZO-1 RNA or proteins 
expression in MPA-treated Caco-2 cells as compared to control cells (Fig. 4.2 E-G). 
Collectively, the gene expression data correlate well with the gene-specific epigenetic changes 
induced by MPA treatment in Caco-2 monolayer cells.  
4.4.3 MPA treatment activates p38MAPK and ATF-2 at epigenetic level in Caco-2 cells. 
Recently it was reported that p38MAPK increases TJs permeability in IL-1β treated Caco-2 
through activation of MLCK pathway [255]. In this study we aimed to extend our previous 
knowledge and explored whether p38MAPK acts upstream of MLCK/MLC-2 pathway in MPA-
treated Caco-2 cells. Towards this end, firstly, we assessed the epigenetic status of p38MAPK 
and ATF-2 genes at their promoter regions by ChIP assay in MPA treated or untreated Caco-2 
monolayer cells. Our ChIP results showed that the activation histone modification mark 
(H3K4me3) was increased significantly at the promoter region of p38MAPK and ATF-2 genes, 
respectively in MPA treated cells (Fig. 4.3 A & B). Concomitantly, repression mark 
(H3K27me3) was decreased significantly at the promoter region of p38MAPK and ATF-2 genes, 
respectively, as compared to controls (Fig. 4.3 A & B). The transcriptionally active epigenetic 
state of p38MAPK and ATF-2 was confirmed by the mRNA expression analysis that showed 
significant increase in p38MAPK and ATF-2 expression after MPA (Fig. 4.3 C). 
4.4.4 Inhibition of p38MAPK via SB counteracts the altered expression of MLCK, MLC-
2, and occludin genes in MPA-treated Caco-2 cells. 
In order to test whether MPA indeed regulates p38MAPK-dependent expression of MLCK 
pathway and thereby the TJs defects, we performed the p38MAPK inhibition and studied its 
effect at the functional level. The chemical inhibitor SB203580 (SB), a representative of 
pyridinlimidazole, is a specific inhibitor of p38MAPK and is widely used in inhibitory studies to 
attenuate the activity of p38MAPK and its downstream signaling activities in various 
physiological processes [271]. Our results showed that p38MAPK inhibition in MPA treated 
Caco-2 cells prevented any significant change in expression of MLCK, MLC-2, phosphorylated 
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MLC-2 (pMLC-2) and Occludin protein as compared to DMSO only treated cells (Fig. 4.3 D-G). 
While the expression of ZO1 was found unaltered by MPA or MPA+SB treated Caco-2 cells 
(Fig. 4.3 H).  
4.4.5 p38MPAK inhibition partially reverses MPA-induced TJs dysfunction 
The maintenance of normal protein levels of MLCK, MLC2, and occludin after p38MAPK 
inhibition prompted us to study the functional properties of Caco-2 monolayer in the presence of 
SB.  The intactness of Caco-2 cells differentiated into polarized confluence monolayer can be 
measured quantitatively as TEER value and the sum of the resistance indicates the integrity of 
the monolayer barrier maintained by TJs in the apical surface of the cells. Any damage to the 
intactness of monolayer results in reduced TEER value. In accordance with the literature, 
exposure of Caco-2 monolayer to MPA significantly decreased TEER at 24 h after treatment, 
and the TEER was significantly further decreased by 72 h as compared to the control cells (Fig. 
4.3 I). Similarly, FD4 permeability analysis (traditionally used to measure the movement of 
small molecules across the intestinal epithelium in vivo) following 72 h MPA treatment showed a 
time-dependent increase across (from the apical to the basolateral side) the Caco-2 monolayer, as 
expected (Fig. 4.3 J).  
Interestingly, when MPA-treated Caco-2 cells monolayers were co-incubated with the inhibitor 
for p38MAPK, very significant preservation of TEER (approximately 50%) was observed as 
compared to only MPA-treated Caco-2 cells (Fig. 4.3 I-J). Similarly, 50% reduction in the FD4 
leak on the basolateral side of the Caco-2 cell monolayer was measured as compared to only 
MPA-treated monolayer (Fig. 4.3 J). Collectively, these results confirm that the Caco-2 
monolayer paracellular permeability is significantly increased after MPA exposure and that can 





Figure 4.1: MPA treatment increases global histone acetylation in Caco-2 cells.  (A) Dot-blot 
analysis; Caco-2 cells were cultured in 6-well plates and post confluence monolayers were treated either 
with 10µM MPA or DMSO for indicated time points. Total proteins were extracted and a volume of 2 μl 
from each time point was spotted on nitrocellulose membrane, dried and then probed with anti-H3K9ac 
and anti-H4K8ac antibodies. (B) Western blot analysis; Total cell proteins were resolved on 12.5% SDS-
PAGE gels and, immunoblotted using anti-H3K9ac & anti-H4K8ac specific antibodies. β-actin was used 
as a loading control. (C and D). Bar graphs representing the densitometric analysis of three independent 
experiments from Western blot (B) using the Lab image software. Differences between two groups were 
analyzed by the two-tailed Student‟s t-test and of more than two groups by one-way ANOVA with 
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Bonferroni posttest (n = 3) and the values were expressed as means ± SEM. *P <0.05, **P < 0.01, ***P < 
0.001 when compared with control cells. 
 
Figure 4.2: causes epigenetic activation of MLCK/MLC-2 pathway and tight junction genes 
(occludin). (A-D) Caco-2 cells were grown for 13 days post-confluence to form differentiated monolayers 
and then treated for 72 h with MPA or DMSO. ChIP was performed using anti-H3K4me3 (activation 
mark) or anti-H3K27me3 (repression mark), followed by real time PCR using promoter-specific primers 
of the target genes (MLCK, MLC-2, Occludin and ZO-1). Levels of H3K4me3 or H3K27me3 was 
measured as %age input in the MPA treated as compared to the untreated cells. (E and F) Western blot 
analyses of MLCK, MLC-2, occludin and ZO-1 after MPA treatment. Whole cell protein lysates were 
resolved on SDS-PAGE gels and immunoblotted using of anti-MLCK, anti-MLC-2, anti-occludin and 
anti-ZO-1 specific antibodies. β-actin was used as a loading control for an equal amount of protein. 
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Densitometric analysis was done using the Lab image software on three independent experiments. 
Differences between two groups were analyzed by the two-tailed Student‟s t-test and of more than two 
groups by one-way ANOVA with Bonferroni posttest. (G) DMSO treated Caco-2 monolayer cells. The 
values were expressed as means ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 when compared with control 
cells. (n = 3). 
4.4.6 Inhibition of p38MAPK through SB demolishes increased promoter activity of 
downstream targets of p38MPAK in MPA-treated Caco-2 cells. 
Next, we analyzed whether the protein expression changes seen after the inhibition of p38MAPK 
are due to the epigenetic remodeling at the promoter regions of these genes or are due to protein 
stability. In accordance with the expression data of downstream targets of p38MAPK, the 
epigenetic signature at the promoter regions of MLCK, MLC-2, and Occludin, but not ZO1, was 
restored to the epigenetic status seen in control cells (Fig. 4.4 A-D) by SB use. Similarly, by use 
of SB, the promoter region of ATF2, but not p38MAPK, showed the normal chromatin signature 
seen in control cells (Fig. 4.4 E & F). These results were further confirmed by mRNA expression 
analysis, which showed that pretreatment with SB restored the MPA induced gene expression 
changes in Caco-2 cells while it had no significant inhibitory effects on mRNA expression of the 




   
Figure 4.3: p38MAPK regulates MLCK/MLC-2 pathway and its inhibition partially prevents 
MPA-induced TJs dysfunction. (A-B) Epigenetic status at the promoter regions of p38MAPK & ATF-2 
genes MPA or DMSO treated Caco-2 monolayer cells. ChIP was performed with antibodies specific to 
the activation mark (H3K4me3) or repression mark (H3K27me3), followed by real time PCR analysis. 
Relative intensity of activation mark (H3K4me3) or repression mark (H3K27me3) were measured as 
%age input. (C) Bar graph showing the p38MAPK & ATF-2 mRNA expression. (D-H) Western blots and 
the corresponding densitometric data showing the effect of SB on the expression of MLCK/MLC-2 
pathway and tight junction proteins (occludin & ZO-1). (I and J) Line graphs showing the transeplithelial 
electrical resistance (TEER) (I) and paracellular flux (FITC-dextran) (J) assay results obtained either in 








Figure 4.4: Inhibition of p38MAPK counteracts MPA-mediated epigenetic remodeling. Effect of 
SB203580 on promoter activity of p38MAPK mediated MLCK/MLC-2 pathways and TJs genes in MPA-
treated Caco-2 Cells. (A – F) Bar graphs showing the epigenetic status at the promoter regions of MLCK, 
MLC-2, occludin, ZO-1, p38MAPK and ATF-2 genes in either presence or absence of p38MAPK 
inhibitor. The ChIP-qPCR data was expressed as means ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 
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when compared with control cells. Differences between two groups were analyzed by the two-tailed 
Student‟s t-test and of more than two groups by one-way ANOVA with Bonferroni posttest. 
 
Figure 4.5: p38MAPK inhibition preserves normal MLCK/MLC-2 gene expression in Caco2 cells 
treated with MPA. Bar graphs showing the mRNA expression levels of MLCK and MLC-2 (A), 
occludin and ZO-1 (B), and p38MAPK and ATF-2 (C) in either presence or absence of p38MAPK 
inhibitor. Values are expressed as means ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 when compared 
with control cells. Differences between two groups were analyzed by the two-tailed Student‟s t-test and of 
more than two groups by one-way ANOVA with Bonferroni posttest.  
4.5 Discussion 
Regulation of TJs barrier function, that controls paracellular movement, is a vital and complex 
process involving complicated intracellular signaling pathways and organization of TJs proteins 
leading to influence the passage of ions and solutes via paracellular movement across the 
epithelial monolayer [272;273]. On the basis of initial morphological descriptions, TJs were 
characterized as a defined structure, both physiologically and morphologically [274]. However, 
later it was accepted that TJs are a dynamically regulated structure [275;276]. The barrier 
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function of epithelial monolayer depends upon the continuity of the monolayer and intact TJs 
[272;277;278]. Intestinal barrier dysfunction through TJs disruption is characterized by increased 
paracellular permeability along with altered expression and organization of TJs proteins 
[242;279]. Subsequently, other investigators and we have reported MLCK activation, which 
directly leads to the phosphorylation of MLC-2, as a common final pathway of acute TJs 
regulation in response to a broad range of physiological or pathophysiological stimuli 
[253;280;281]. Phosphorylation of MLC-2 through activated MLCK alone is sufficient to 
increase TJs permeability, which is associated with redistribution of ZO-1 and occludin [21]. 
Previously, we have shown that therapeutic dose of MPA caused the increased permeability of 
Caco-2 monolayer, and this outcome is accompanied by increased activity of MLCK/MLC-2 
pathway [253]. In this context, it is interesting to note that proinflammatory cytokine (IL-1β) 
induced increase in intestinal TJs permeability in both in vitro and in vivo models is mediated 
through p38MAPK/ATF-2-dependent regulation of MLCK activity [255]. In this study, we 
wanted to extend our previous knowledge of TJs regulation via MLCK pathway in response to 
MPA. Our data highlight that MPA alters the chromatin structure leading to deregulated 
expression of genes implicated in TJs function. We identified that p38MAPK and ATF-2 
pathway is activated in MPA treated Caco2 monolayer and this pathway was found regulate the 
MLCK/MLC-2 activity. Interestingly, pharmacological inhibition of p38MAPK counteracted the 
altered gene expression of MLCK/MLC-2 and thereby maintained the normal function of TJs. 
Chromatin structure is modulated by the well-known documented posttranslational modification 
of histone proteins [282]. More than 100 different types of posttranslational modifications that 
include; acetylation, methylation, phosphorylation and ubiquitination can occur to the amino-
terminal tails of histones, which form the nucleosomes of chromatin [283;284]. Majority of these 
modifications remain poorly understood, however, considerable progress has been made in the 
understanding of lysine acetylation and methylation of histones in recent years. Lysine 
acetylation is mostly correlated with nucleosome assembly, chromatin accessibility and 
transcriptional activity, whereas lysine methylation effects depend upon the modified residue 
[284]. Acetylated H3K9 [285] and H4K8 are well-known epigenetic markers that are present at 
the promoter regions of transcriptionally active genes [286]. Their levels are strongly correlated 
with the gene expression therefore referred as “transcription-linked” histone marks [286;287]. 
Our global histone acetylation analysis showed significant increase in acetylation at H3K9 and 
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H4K8. This global chromatin change observed after MPA treatment is in agreement with a 
recent report showing that MPA treatment induces global H3/H4 acetylation in CD4(+)T cells to 
exert therapeutic effects in systemic lupus erythematosus patients [268]. In this context, it is 
interesting to note that hydroxamic acid derivatives of MPA were shown to function as histone 
deacetylase (HDAC) inhibitors [288]. Owing to these evidences, it is interesting to speculate that 
MPA might exert its therapeutic effect on immune cells not only by blocking IMPDH, but also 
by acting as epigenetic modifier.  And this epigenetic effect might also occur in non-immune 
cells such as epithelial cells leading to gene expression changes and unwanted phenotypic 
changes.    
Trimethylation of H3K4 is found at more than 90% of the RNA polymerase II binding regions 
[289] at the promoter region of protein coding genes and is linked to gene activation, whereas 
trimethylation of H3K27 is linked to repression of the gene [289;290]. Our ChIP-qPCR data 
showed significant enrichment of H3K4me3 at the promoter regions of MLCK and MLC-2 
genes, enrichment of H3K27me3 at the promoter region of Occludin, while no change in 
H3K4me3 and H3K27me3 levels at ZO-1 promoter region after MPA treatment. The gene 
expression analyses at transcriptional and translational level further strengthened the epigenetic 
activation of MLCK and MLC-2 genes and repression of occludin gene. Interestingly, Inhibition 
of p38MAPK with SB prevented the MPA mediated epigenetic changes as well as the gene 
expression pattern. Presence of SB together with MPA, significantly but not completely reduced 
the MPA induced TJs permeability, suggesting role for additional signaling pathways/proteins in 
TJs deregulation in MPA-treated Caco-2 cells. In view of current data, it would be interesting to 
check whether p38MAPK conditional knockout mice could alleviate or completely block the 
MPA-mediated TJs dysfunction. Therefore, a more detailed analysis of TJs proteins regulation as 
well as their regulating pathway(s) is necessary to understand the mechanism of leak flux 
diarrhea in in vitro model that is comparable to in vivo model of MPA therapy. 
4.6 Conclusions 
In summary, this study provides new insights and an essential understanding into the 
mechanisms of MPA-mediated decrease in intestinal epithelial barrier function. Our data pointed 
out epigenetic activation of p38MAPK, ATF-2, MLCK and MLC-2 genes whereas repression of 
occludin gene at promoter level (Fig. 4.6). To the best of our knowledge, this is the first in vitro 
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experimental study that provides direct evidence to indicate the role of chromatin remodeling in 
the p38MAPK-dependent MLCK pathway activation in response to MPA exposure. From these 
results, it can be hypothesized that comparable barrier function modulations may occur in the 
patients under MPA therapy leading to GI tract complication in some organ transplanted patients. 
Figure 4.6: Proposed mechanism of MPA-induced TJs assembly deregulation in Caco-2 cells monolayer. 
Proinflammatory cytokines (observed in IBD) activates directly or through p38MAPK the MLCK 
pathway which leads to the altered TJs proteins contents and composition in TJs assembly, resulting 
compromised epithelial barrier function. This compromised barrier function contributes to leaky style 
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Activation of the p38MAPK-dependent MLCK/MLC-2 pathway consequently reorganizes F-actin base 
cytoskeleton, redistribute ZO-1 and occludin proteins of TJs assembly, resulting in increased permeability 
of Caco-2 monolayer.  Abbreviations: MPA- mycophenolic acid, p38MAPK- p38 mitogen activated 
protein kinase, ATF-2- activating transcription factor-2, MLCK- myosin light chain kinase, MLC-2- 
myosin light chain-2, TJs- tight junctions, ZO-1- Zonula Occludins, IL-1β- Interleukin-1 beta, TNF-α- 
Tumor necrosis factor-alpha, INF-γ- Interferon-γ, IMPDH-2- Inosine-5'-monophosphate dehydrogenase 
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5.1 Abstract 
Mycophenolic acid (MPA) is prescribed to maintain allograft in organ-transplanted patients. 
However, gastrointestinal (GI) complications, particularly diarrhea, are frequently observed as 
side effect following MPA therapy. We recently reported that MPA altered tight junctions (TJs) 
mediated barrier function in a Caco-2 cells monolayer model system. This study investigates 
whether MPA induces epigenetic changes which lead to GI complications, especially diarrhea? 
We employed a ChIP-O-Proteomics approach to identify proteins associated with active 
(H3K4me3) as well as repressive (H3K27me3) chromatin histone modifications in MPA-treated 
cells, and characterized the role of midkine, a H3K4me3-associated protein, in the context of 
epithelial monolayer permeability. We identified a total of 333 and 306 proteins associated with 
active and repressive histone modification marks, respectively. Among them 241 proteins were 
common both in active and repressive chromatin, 92 proteins were associated exclusively with 
the active histone modification mark, while 65 proteins remained specific to repressive 
chromatin. Our results show that 45 proteins which bind to the active and seven proteins which 
bind to the repressive chromatin region exhibited significantly altered abundance in MPA treated 
cells as compared to DMSO control cells. A number of novel proteins whose function is not 
known in bowel barrier regulation were among the identified proteins, including midkine. Our 
functional integrity assays for Caco-2 cell monolayer showed that inhibition of midkine 
expression prior to MPA treatment can completely block MPA-mediated increase in barrier 
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permeability. The ChIP-O-Proteomics approach delivered a number of novel proteins with 
potential implication in MPA toxicity. In line with this it can be proposed that midkine inhibition 
could be a potent therapeutic approach to prevent MPA-mediated increase in TJ permeability as 
well as leak flux diarrhea in organ transplanted patients. 
5.2 Introduction 
Mycophenolic acid (MPA) is a reversible yet highly selective non-competitive inhibitor of 
inosine 5′-monophosphate dehydrogenase-2 (IMPDH-2) enzyme. IMPDH-2 is expressed in 
proliferating immune cells (B & T cells) and is involved in the biosynthesis of guanine 
nucleotide via de novo pathway [1;291]. This inhibitory property led to classify MPA as an 
immunosuppressant which is prescribed to organ transplant patients to prevent graft rejection 
[292]. Same as most available immunosuppressants, MPA is associated with gastro intestinal 
(GI) complications including diarrhea [4]. Hence, more attention is needed either to focus on 
dose related strategies or to explore mechanisms of action that can help to minimize MPA 
associated side effects in organ transplant patients.   
Drugs may alter the epigenetic status of exposed cells via direct or indirect mechanisms [293]. 
Hydralazine, which is prescribed to treat hypertension, is known to inhibit DNA methylation in 
T-cells and to induce autoreactivity as a side effect [294]. While acute exposure of isotretinoin, a 
drug prescribed to treat severe acne as well as various skin cancers influences the transcriptional 
activity of transcriptional factor FoxO1. FoxO1 activates the promoter of FoxO1-binding site 
genes via all-trans-retinoic acid and consequently causes many side effects such as 
hepatotoxicity, hair loss, bone toxicity, hypertriglyceridemia etc. [293;295]. Recently, it has been 
reported that MPA downregulates histone deacetylases (HDAC2, HDAC7 & SIRT1) and 
upregulates histone acetyltransferases (CREBBO & PCAF) in CD4+ T cells isolated from 
systemic lupus erythematosus patients [296]. Therefore, we hypothesized that epigenetic changes 
may be involved in the etiology of GI complications observed in organ transplant patients after 
MPA therapy.  
The main objective of this study was to correlate the pathophysiology of GI complications, 
especially MPA-induced diarrhea in organ transplanted patients, with the altered expression of 
Chromatin immunoprecipitation-O-Proteomics (ChIP-O-Proteomics) precipitated protein(s). Our 
ChIP-O-Proteomics results indicate that MPA treatment increases the expression of midkine as 
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well as its association with H3K4me3-marked chromatin. Functional analysis of differentiated 
and polarized Caco-2 cells monolayer revealed that midkine inhibitor (iMDK) can significantly 
inhibit the MPA mediated increase in monolayer permeability.   
5.3 Material and Methods  
5.3.1 ChIP-O-Proteomics 
Caco-2 cells were grown for 13 days post-confluence to establish a monolayer of differentiated 
and polarized cells resembling enterocytes. Monolayers were incubated with MPA (10 µM) or 
DMSO (as a control) for 72 h. ChIP assay was performed as following; Caco-2 cells were fixed 
with 37% formaldehyde at a final concentration of 1% for 30 min at room temperature (RT) 
followed by quenching with glycine (0.125M) for an additional 5 min at RT. Cells were 
collected in ice-cold PBS and equal numbers of cells from each treatment group were lysed with 
lysis buffer (Red ChIP Kit
TM
, Diagenode). Chromatin was sheared using a Branson Sonifier 250 
in shearing buffer according to the manufacturer‟s instructions (Red ChIP Kit
TM
, Diagenode). 
After pre-clearing, chromatin from each treatment was divided into three aliquots. An aliquot 
from each sample was either incubated with active histone mark antibody (anti-H3K4me3; 
abcam) or repressive histone mark antibody (anti-H3K27me3; Milipore), or with IgG (One Day 
Kit
TM
, Diagenode) for overnight at 4°C. Antibody-chromatin complexes were further incubated 
with pre-activated Protein-A magnetic beads, washed and sample was divided into two portions. 
One portion was treated with proteinase-K to use for a promoter study at DNA level and the 
other portion was used for the identification of chromatin binding proteins using mass 
spectrometry.  
5.3.1.1 Promoter assay:  
DNA-protein cross-linking was reversed by degrading DNA binding proteins with proteinase K. 
DNA was purified with DNA slurry (One Day Kit
TM
, Diagenode) and quantified by NanoDrop 
(NanoDrop 2000C, peqlab, Thermo Scientific). ChIP-precipitated genomic DNA was used as a 
template in a SYBR green (Roche, Manheim, Germany) based real time PCR reaction. 
Comparative threshold cycle (CT) method (2
-ΔΔCT
) [297] was used to analyze the  real time PCR 
data and described as fold change. Data was normalized to GAPDH, a housekeeping internal 




5.3.1.2 Proteins purification from chromatin-antibody complexes  
Glycine elution method was used to isolate proteins from chromatin-antibody complexes. 
Briefly, glycine buffer (pH 2.5) was added to each sample for 5 min with agitation at RT. 
Supernatant was neutralized by adding Tris (pH 8.0). To eliminate interfering substances such as 
detergents, salts, phenolic acid and nucleic acid, proteins were precipitated overnight by acetone 
precipitation and the pellets was dried in a SpeedVac concentrator (UNIVAPO 150 H, 
Germany). Proteins were then reduced with 25 mM Dithiothreitol (DTT), alkylated by adding 
100 mM Iodoacetamide (IAA) and subject to in solution trypsin digestion. To stop the trypsin 
activity each sample was acidified by incubating with 5% Trifluoroacetic acid (TFA) and the 
supernatant was collected, dried using a SpeedVac, reconstituted in 2% acetonitrile/0.1% formic 
acid (v:v) and prepared for nanoLC-MS/MS analysis. 
5.3.1.3 nanoLC-MS/MS analysis  
For mass spectrometric analysis, samples were enriched on a self-packed reversed phase-C18 
precolumn (0.15 mm ID x 20 mm, Reprosil-Pur120 C18-AQ 5 µm, Dr. Maisch, Ammerbuch-
Entringen, Germany) and separated on an analytical reversed phase-C18 column (0.075 mm ID x 
200 mm, Reprosil-Pur 120 C18-AQ, 3 µm, Dr. Maisch) using a 30 min linear gradient of 5-35 % 
acetonitrile/0.1% formic acid (v:v) at 300 nl min
-1
. The eluent was analyzed on a Q Exactive 
hybrid quadrupole/orbitrap mass spectrometer (ThermoFisher Scientific, Dreieich, Germany) 
equipped with a FlexIon nanoSpray source and operated under Excalibur 2.4 software using a 
data-dependent acquisition method. Each experimental cycle was of the following form: one full 
MS scan across the 350-1600 m/z range was acquired at a resolution setting of 70,000 FWHM, 
and automatic gain control (AGC) target of 1*10e6 and a maximum fill time of 60 ms. Up to the 
12 most abundant peptide precursors of charge states 2 to 5 above a 2*10e4 intensity threshold 
were then sequentially isolated at 2.0 FWHM isolation width, fragmented with nitrogen at a 
normalized collision energy setting of 25%, and the resulting product ion spectra recorded at a 
resolution setting of 17,500 FWHM, and AGC target of 2*10e5 and a maximum fill time of 60 
ms. Selected precursor m/z values were then excluded for the following 15 s. Two technical 
replicates per sample were acquired. 
5.3.1.4 Data processing  
Peak lists were extracted from the raw data using Raw2MSMS software v1.17 (Max Planck 
Institute for Biochemistry, Martinsried, Germany). Protein identification was achieved using 
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MASCOT 2.4 software (Matrixscience, London, United Kingdom). Proteins were identified 
against the UniProtKB Homo sapiens reference proteome v2015.02 (20268 protein entries along 
with a set of 51 contaminants commonly identified in our laboratory). The search was performed 
with trypsin as enzyme and iodoacetamide as cysteine blocking agent. Up to two missed tryptic 
cleavages and methionine oxidation as a variable modification were allowed for. Search 
tolerances were set to 10 ppm for the precursor mass and 0.05 Da for fragment masses, and ESI-
QUAD-TOF specified as the instrument type. 
Scaffold software version 4.4.1.1 (Proteome Software Inc., Portland, OR) was used to validate 
MS/MS based peptide and protein identifications. Peptide identifications were accepted if they 
could be established at greater than 95.0% probability by the Percolator algorithm. Protein 
probabilities were assigned by the Protein Prophet algorithm [298]. Protein identifications were 
accepted if they could be established at greater than 99% by the Percolator algorithm and 
contained at least 2 identified peptides. Protein hits that contained similar peptides and could not 
be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Proteins sharing significant peptide evidence were grouped into clusters. Proteins 
were annotated with GO terms from NCBI downloaded on Feb 23, 2015. [299]. Relative 
quantification of proteins in the samples was achieved by Analysis of Variance (ANOVA) of 
normalized Spectral Counts using a Benjamini-Hochberg-corrected p value of 0.1 to judge 
significance. To allow for the calculation of low abundance protein ratios, a value of 3 spectral 
counts was introduced as a plausible minimum where necessary to avoid division by zero issues. 
5.3.2 mRNA Expression Assay: 
Caco-2 cells were grown and treated as previously described [64;300]. Briefly, differentiated and 
polarized Caco-2 cells monolayers were treated with MPA or iMDK+MPA or MPA+iMDK or 
DMSO (control) for 72 h. Cells were harvested and the total RNA was isolated using the Trizol 
method. Total RNA was reverse transcribed and the expression of the midkine gene was 
quantified by real time PCR using cyberGreen as the detecting dye.  
5.3.3 Cell cytotoxicity assays  
Differentiated and polarized monolayers of Caco-2 cells were treated with MPA or iMDK (0-
100nM) +MPA or DMSO for 72 h. Following 72 h of treatment, supernatants were collected to 
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measure the lactate dehydrogenase (LDH) marker using cytotoxicity detection kit (LDH FS, 
Diaysys) according to the manufacturer‟s guidelines.  Cells were collected and the trypan blue 
exclusion test performed to assess cell viability as previously described [64;301;302]  
5.3.4 Caco-2 monolayer integrity  
Trans epithelial electrical resistance (TEER) and FITC-dextran (FD4) assays were performed as 
described previously [300] to assess the intactness of the paracellular pathway in the monolayer 
between adjacent cells. Briefly, differentiated and polarized monolayers of Caco-2 cells were 
established on transwell insert membranes. Each monolayer was treated with MPA or 
iMDK+MPA or MPA+iMDK or DMSO (control) for 72 h. TEER values were recorded at 
several indicated time points. Following 72 h treatment and TEER reading, each monolayer was 
washed and FD4 dye was added to the apical chamber for 2 h. Samples were collected from 
basolateral chamber and dye concentrations were measured using a Lambda fluoro 320 
fluorescence plate reader (MWG Biotech, Ebersberg, Germany).  
5.4 Results and discussion: 
We recently reported that MPA treatment increases the expression of the MLCK-MLC2 pathway 
in Caco-2 cell monolayers [64]. Our subsequent results showed that MPA treatment alters the 
expression of MLCK-MLC2 by modulating the epigenetic status at their respective promoter 
regions [300]. To identify the proteins that participate or associate with epigenetic changes 
occurring at chromatin level during MPA treatment, we undertook a ChIP-O-Proteomics 
approach (Fig. 5.1 A). Towards this, we first performed ChIP, and the immunoprecipitated 
sample was aliquoted into two parts prior to separation of DNA and protein complex. One part 
was analyzed for MLCK promoter epigenetic status (for quality control), while the other part 
was used for ChIP-O-Proteomics analysis. Traditional ChIP-qPCR revealed that the promoter 
region of MLCK, in MPA-treated Caco-2 cells, is enriched for H3K4me3 (Fig. 5.1 B & C), 
further confirming our gene expression data and allowing us to proceed with the ChIP-O-
Proteomics approach. Our promoter assay results of MLCK are consistent with these findings 
[303;304] .  
We used label free, quantitative spectral counting based ChIP-O-Proteomics approach to identify 
and quantify the proteins associated with either H3K4me3 (active) or H3K27me3 (repressive) 
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histone marks. Proteins associated with chromatin regions that represent either active or 
repressive promoters of protein coding genes were identified by mass spec using the following 
criteria {protein threshold = 99%, minimum number of peptide = 2, peptide threshold = 95%, 
false discovery rate = 1%} for protein selection. Analysis of variance (ANOVA) was performed 
with multiple testing correction (Hochberg-Benjamini-Correction) using Scaffold software to 
obtain a quantitative profile of proteins identified at ≥99% confidence using label free spectral 
counting. Proteins precipitated by an IgG control were subtracted from the results list. Our ChIP-
O-Proteomics approach identified a catalog of proteins at both the active and/or repressive 
promoter regions.  We identified a total of 333 proteins associated with anti-H3K4me3, and 306 
proteins associated with anti-H3K27me3 antibodies in MPA-treated cells as well as in DMSO 
(control) treated cells. Among these proteins, 241 were commonly found at both active and 
repressive chromatin (Fig. 5.1 D). 92 proteins were found to associate specifically with the active 
histone modification mark, while 65 proteins remained specific to repressive chromatin (Fig. 5.1 
D). A number of proteins (i.e., Cdx-1, TOP2-A, H2AFX, RCC1 & RBBP4 etc.) were previously 
identified as H3K4me3-associated in mouse embryonic stem cells [305]. Similarly, IL3, 
HNRPM, 40S ribosomal proteins, 60S ribosomal proteins and LAP2B were identified as 
H3K4me3-associated proteins in HeLa cells [306]. In addition, however, we report here sets of 
protein candidates (Supplementary data file 1) that have not been previously associated with 
active or repressive chromatin marks. This discrepancy with other studies may be due to the 
specific cell system and enrichment scheme used here. Unlike genomics which is rather constant, 
proteomics is dynamic in nature [307] differing from cell type to cell type and even within same 
cells under different environmental conditions.  
Next, we analyzed the differential protein complements associated with active and repressive 
chromatin regions of MPA-treated Caco-2 cells (Fig. 5.1 E & F). Our mass spec data revealed 
altered enrichment of 45 candidates at active chromatin region and seven candidates at repressive 
chromatin region in MPA treated Caco-2 cells as compared to DMSO (control) treated cells. 
(Table 5.1). These differentially enriched proteins are known to be involved in the regulation of 
transcription, cell cycle, chromatin structure, chromosome segregation and condensation, while 
their altered expression results in the etiology of certain diseases.  
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Interestingly, our nanoLC-MS/MS results showed significant increases in spectral counts for 
midkine protein in MPA-treated cells. This result was further confirmed at the epigenetic and 
mRNA levels (Fig 5.2 A-D).  Midkine is a multifunctional cytokine or growth factor that 
provokes various biological processes including growth, migration, survival, repair and gene 
expression [308]. Apart from its normal function, overexpression of midkine is considered to 
play an important role in the etiology of various diseases such cancer and inflammatory diseases 
[309]. Elevated concentrations of circulating midkine have been observed in the serum of 
Crohn‟s disease (CD) [310] and ulcerative colitis (UC) [311] patients. Increased TJ permeability 
via different cytokines is also associated with CD and UC diseases [312]. However, the role of 
midkine in the regulation of the TJ assembly has not been reported in the context of GI tract 
complications. To understand whether MPA increases midkine mediated monolayer 
permeability, we performed midkine inhibitor (iMDK) studies.  In order to check any possible 
cytotoxic effect of iMDK on Caco-2 cell monolayer, the cells were incubated with either MPA 
alone or in combination with varying concentrations of iMDK and tested for cell viability. These 
results showed that MPA treatment alone, as well as co-treatment with iMDK (5-25 nM), had no 
significant cytotoxic effect as compared to control cells (Fig. 5.3 A & B) which were further 
confirmed by measuring cytotoxicity biomarker, lactate dehydrogenase (LDH). However, higher 
concentrations of iMDK (50 nM) caused significant cytotoxicity (Fig. 5.3 A & B). We further 
evaluated the inhibitory concentration of iMDK to prevent midkine expression in MPA-treated 
Caco-2 cells. Our results show that MPA mediated increased expression of midkine was 
prevented in Caco-2 cell monolayers by pretreatment with non-cytotoxic concentration of iMDK 
(25nM) (Fig. 5.3 C). We assessed the Caco-2 cell monolayer integrity using TEER and FD4-flux 
assays in different treatment groups; (1) MPA-treated group, (2) iMDK+MPA treated group 
(iMDK was added 1 h prior to co-incubation with MPA for next 72 h), (3) MPA+iMDK (MPA 
treatment for 60 h and then followed by co-incubation with iMDK for 12 h) (Fig. 5.2 E). TEER 
and FD4flux assays are well established parameters which are traditionally used to assess 
epithelial monolayer integrity [313]. Epithelial monolayer integrity is lost either to cell death or 
compromised TJ assembly. TJ is a complex but dynamic structure; different types of stimuli 
increase TJ permeability via different types of cellular signaling pathways in various disease 
models  [312]. In agreement with our previous results, TEER values of MPA-treated confluent 
Caco-2 cell monolayers significantly dropped in a time-dependent manner as compared to 
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control monolayer and concomitantly FD4 dye flux concentration increased across the Caco-2 
cell monolayer. However, pretreatment with midkine inhibitor (iMDK) significantly blocked 
MPA mediated decrease TEER values, and increased FD4 dye flux across Caco-2 monolayer 
(Fig. 5.2 E & F). On the other hand, when iMDK was added at the later stage of MPA treatment, 
no significant differences were observed compared to MPA treatment alone (Fig. 5.2 E & F). In 
this study we found midkine in the chromatin fraction; in earlier studies, midkine was found to 
localize to the nucleus and nucleolus in HepG2 cells and to be involved in the transcription of 
45SrRNA gene [314;315].  
ChIP-o-Proteomics approach is relatively new but effective technique to identify novel 
chromatin associated targets [316;317]. Using our modified protocol, we could identify number 
of new proteins associated with the active and repressive chromatin marks. Furthermore, 
semiquantitative spectral counting approach yielded differential enrichment of 45 candidates at 
active chromatin region and seven candidates at repressive chromatin region in MPA treated 
cells as compared to controls. MPA at the used concentration showed no significant cytotoxic 
effects alone or in combination with midkine inhibitor (iMDK). Inhibition of midkine 
significantly blocked the MPA mediated epithelial monolayer permeability. These results 
indicate that combination of immunosuppressive drugs with additional substance like Midkine 
inhibitor (iMDK) may be helpful to avoid the unwanted effects of immunosuppressive regime. 
However, further detailed in vivo and in vitro studies are required to make the 





Figure 5.1: Schematic overview of ChIP-O-Proteomics experimental steps. (A) Schematic overview 
of ChIP-O-Proteomics experimental steps. Differentiated and polarized Caco-2 cell monolayers were 










was used as a 
background. 
Each sample was 
aliquoted into 
two portions. 




real time PCR. 
The other portion 
was used to identify and quantify promoter binding proteins using mass spectrometry. Three biological 
replicates each one with at least two technical replicates were performed for each group. (B & C) ChIP-
DNA was subjected to real time PCR with specific primer pair of MLCK promoter region. Each bar 
represents abundance or depletion of activation mark (H3K4me3) and/or repression mark histone mark 
(H3K27me3) in the promoter of MLCK gene. Data is presented as fold change by taking the control as 
1.0 and error bar indicate means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control 
(DMSO) (D). Venn diagram show the number of identified proteins associated with active promoter and 
repressive promoter following subtraction of IgG precipitated proteins as background. (E & F). Scaffold 
analysis of gene ontology (GO) for the ChIP-O-Proteomics identified proteins. (E). H3K4me3 associated 
proteins and (F) H3K27me3 associated proteins. Pie charts represent the percentages of the identified 




Figure 5.2: Influence of MPA on the expression and activation of midkine gene and Caco-2 cells 
monolayer integrity. (A-D) Influence of MPA on the expression and activation of midkine gene. (A) Quantification of 
midkine protein by spectral count after MPA treatment as compared to DMSO (control) cells. Asterisks indicate that the midkine 
protein was significantly up-regulated after MPA treatment. (B) Expression (mRNA) of midkine gene after MPA-treatment. 
Expression of mRNA of midkine was investigated using quantitative real time PCR. (C & D) Influence of MPA treatment on the 
enrichment or depletion of histone active modification mark (H3K4me3) and repressive histone modification mark (H3K27me3) 
in the promoter of the midkine gene. (E & F) Caco-2 cells monolayer integrity. Caco-2 cells were seeded on the transwell insert 
membrane. Differentiated and polarized Caco-2 cells were treated as described in material and method. (E) TEER was measured 
at the indicated times in the graph. (G) Following 72 hrs incubation, FITC-dextran dye (1mg/ml) was added to the apical 
chamber and dye concentration was measured in the sample collected from basal chamber. TEER and FITC-dextran assay results 
obtained either in presence or absence of midkine inhibitor (iMDK). Error bars indicate means ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001. Differences between two groups were analyzed by the two-tailed student‟s t-test and for more than two groups 




Figure 5.3: Influence of midkine inhibitor (iMDK) on midkine expression and cell viability of MPA-
treated Caco-2. (A) Viability of Caco-2 cells {trypan blue dye exclusion assay} after 72 hrs treatment 
with DMSO (control) and MPA (10µM) alone or in combination with different concentration of iDMK 
inhibitor (0-100nM). Cell viability was markedly decreased when Caco-2 cells were co-incubated with 
iMDK (≥ 50nM) plus MPA (10µM). (B) Cytotoxic effects of midkine inhibitor were assessed by 
performing LDH leakage assay. Significant leakage of cytotoxic marker (LDH) was found after iMDK 
(≥50nM) plus MPA (10µM) treatment. (C) Expression of midkine after 72 hrs treatment with DMSO 
(control), MPA (10µM) alone or in combination with midkine inhibitor (iDMK). iMDK significantly 
inhibits the expression of midkine gene at the concentration of ≥25nM.  Each bar represents separated 
experiment. Data are presented as means ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the 







Table 5.1: Differential proteomic after MPA treatment at histone modifications (H3K4me3 & 
H3K27me3)   
Supplementary Table 


























Q9UN86 Ras GTPase-activating protein-binding 
protein 2 OS 
2.5  0.0067 
mRNA transportation 
P63104 14-3-3 protein zeta/delta  1.1  0.0031 Adaptor protein 
P61978 Heterogeneous nuclear 
ribonucleoprotein K  
1.4  0.0032 
Transcription activation/repression, 
hnRNAs metabolism.  
P07355 Annexin A2  1.2  0.0011 Heat response 
P68104 Elongation factor 1-alpha 1  
1.1  0.0011 
Transcription activity, protein 
synthesis 
Q8IUE6 Histone H2A type 2-B  1.2  0.0087 Chromatin structure 
P62258 14-3-3 protein epsilon  1  0.005 Adaptor protein 
P61254 60S ribosomal protein L26  1  0.0078  
Q01844 RNA-binding protein EWS  1.1  0.003 Repressor 
P68431 Histone H3.1  1.4  0.0011 Chromatin structure 
P16402 Histone H1.3  
1.1  0.00019 
Chromatin structure, regulator of 
individual gene transcription. 
P62249 40S ribosomal protein S16  1.25  0.0042  
Q15691 Microtubule-associated protein RP/EB 
family member 1  
1.1  0.0046 
Microtubule base cytoskeleton 
Q13242 Serine/arginine-rich splicing factor 9  1.1  0.00038 Splicing activity 
P37108 Signal recognition particle 14 kDa 
protein  
1.0  0.0039 
 
Q96AE4 Far upstream element-binding protein 1  1.4  0.0063 Transcriptional activity 
P24534 Elongation factor 1-beta  
1.3  0.0015 
Exchanging EF-1alpha bound GDP to 
GTP 
Q12906 Interleukin enhancer-binding factor 3  1.5  0.00042 Gene regulation, protein synthesis 
P10599 Thioredoxin  1.1  0.00048 Transcription activity, redox reaction 
P62081 40S ribosomal protein S7  1.3  0.0071 rRNA maturation 
P62851 40S ribosomal protein S25  0.9  0.0006  
Q12874 Splicing factor 3A subunit 3  1.3  0.0058 Subunit of A & E complex 
P62857 40S ribosomal protein S28  1.1  0.0043  
P09234 U1 small nuclear ribonucleoprotein C  1.1  0.0054 Splicing activity 
Q14157 Ubiquitin-associated protein 2-like  
1.3  0.00014 
ubiquitin‑proteasome pathway, 
growth and migration of prostate 
cancer cells  
P25398 40S ribosomal protein S12  1.25  0.0082  
Q99459 Cell division cycle 5-like protein  
1.6  0.0032 
Cell cycle regulator, transcription 
activity 
O95793 Double-stranded RNA-binding protein 
Staufen homolog 1  
1.5  0.0028 
Cross linking cytoskeleton, RNA 
component, translation 
P62424 60S ribosomal protein L7a  1.3  0.0074  
Q92522 Histone H1x  1.7  0.008 Chromatin condensation 
Q71UI9 Histone H2A.V  
1.2  0.0017 
Chromosome segregation, cell 
division 
Q9NYL4 Peptidyl-prolyl cis-trans isomerase 
FKBP11  
1.11  0.0065 
Protein folding 




Energy transduction  
P14866 Heterogeneous nuclear 
ribonucleoprotein L  
1.8  0.0022 
Splicing activity, regulator of exon 
inclusion.  
P02545 Prelamin-A/C  
1.7  0.0022 
Nuclear lamina, chromatin 
organization, telomere dynamics 
P20700 Lamin-B1  
1.8  0.002 
Nuclear lamina, chromatin 
organization, telomere dynamics 
P23528 Cofilin-1  
1.4  0.0016 
Cell morphology, cytoskeletal 
organization. 
Q13813 Spectrin alpha chain, non-erythrocytic 1  5.5  0.0038 Cytoskeleton 
P21796 Voltage-dependent anion-selective 
channel protein 1  
1.9  0.0046 
Cell volume, apoptosis 
Q15365 Poly(rC)-binding protein 1  1.8  0.0029 Nucleic acid binding protein 
P53999 Activated RNA polymerase II 2.1  0.006 Stabilizing the  multiproteins 
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transcriptional coactivator p15  transcription complex 
P09327 Villin-1  
2.5  0.005 
Cell morphology, division, migration 
and apoptosis 
P21741 Midkine  
3.8  0.00010 
Growth factor, activator of PI3K, 
MAPK pathways 
Q15366 Poly(rC)-binding protein 2  
2.2  0.0093 
Nucleic acid binding protein, adaptor 
& regulator protein,  
P61586 Transforming protein RhoA  
3   0.0071 
Signal transduction pathway, 






























Q06830 Peroxiredoxin-1  1.67  0.00094 Redox regulation 
P13639 Elongation factor 2  1.67  0.00010 ribosomal translocation 
P12956 X-ray repair cross-complementing 
protein 6  5  0.00098 
Helicase activity, chromosome 
translocation, negative transcription 
regulators, 
Q9ULV4 Coronin-1C  
3.33  0.00044 
cytokinesis, motility, and signal 
transduction 
P14174 Macrophage migration inhibitory factor  1.25  .00058 Pro inflammatory cytokines 
P10599 Thioredoxin  
1.1  0.00010 
Redox reactions, DNA binding 
activity 
Q9NX24 H/ACA ribonucleoprotein complex 
subunit 2  
4.3  0.00010 
Ribosome biogenesis, telomere 
maintenance 
Note: Arrows indicate “” upregulation and “” downregulation of the respective proteins after MPA treatment as compared with DMSO (control 
in fold change.  
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6.1 Abstract 
Immunosuppressant mycophenolic acid (MPA) is prescribed to prevent allograft rejection in 
organ transplanted patients. However, its use is sporadically linked to the leak flux diarrhea and 
other gastrointestinal (GI) disturbances in around 75% of patients through yet unknown 
mechanism(s). Recently, we identified midkine as the modulator of tight junctions (TJs) 
permeability in MPA treated Caco-2 monolayer. In the present study, we explored the possible 
involvement of midkine dependent PI3K pathway in alteration of TJs under MPA treatment.  
Caco-2 cells were grown as monolayer to develop the TJs and were treated for 72 hours with 
MPA alone or midkine inhibitor (iMDK) + MPA or PI3K inhibitors (LY/AMG) + MPA or 
DMSO as control. Caco-2 monolayer integrity was assessed by trans epithelial electrical 
resistance (TEER) and FITC-dextran assays. The epigenetic status, mRNA and protein 
expression of selected genes involved in PI3K pathway and TJs regulation were assessed by 
chromatin immunoprecipitation (ChIP), qRT-PCR, and western blot, respectively. Our functional 
assays showed that PI3K inhibitors (LY/AMG) can significantly inhibit the compromised TJs 
integrity of MPA-treated Caco-2 cells monolayer. ChIP analyses showed a significant epigenetic 
activation of midkine, PI3K, Cdx-2, and claudin-2 genes and epigenetic repression of claudin-1 
gene after MPA treatment. The MPA-induced epigenetic alterations were further confirmed by 
mRNA and protein expression assays after MPA treatment. Collectively, our data show that 
PI3K pathway as the downstream target of midkine which in turn modulates p38MAPK and 
pAkt signaling to alter TJs permeability in Caco-2 cell monolayers treated with MPA. These 
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results highlight the possible use of either midkine or PI3K inhibitors as therapeutic agents to 
prevent MPA induced GI disturbances.    
Key words: Epigenetics, Promoter assay, MPA, PI3K, midkine, Akt, inhibition 
 
6.2 Introduction 
Organ transplantation is accepted as the end stage treatment of the failure organ. In case of organ 
transplantation, immunosuppressive drugs (ISDs) are prescribed to lower the body‟s ability to 
reduce the rejection of transplanted graft [318]. MPA is an immunosuppressant agent available 
as mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), which 
selectively decreases the de novo synthesis of guanine nucleotide pool by inhibiting the 
enzymatic activity of inosine-5′-monophosphate dehydrogenase-2 (IMPDH-2) [319] and halt the  
proliferation of  lymphocytes [320] at S phase.  
Almost all available ISDs including MPA are associated with some forms of GI tract 
complications. These GI complications in organ transplanted patients are initiated by several 
factors that can be categorized as infection (viral, bacterial, fungal and parasitic infections), 
biliary tract diseases, diverticular diseases, perforations, pancreatitis, malignancy and mucosal 
injury and ulceration (prominent diarrhea) (reviewed in [4]). Clinical data show the occurrence 
of a significant number of drug-induced diarrhea incidences in liver and kidney organ 
transplanted patients receiving MPA therapy [24;321]. Diarrhea can result dehydration and 
discomfort in transplanted patients. Although dose reduction may decrease the chance of 
diarrhea but it might increase the rate of acute graft rejection. To overcome this problem, two 
possibilities were proposed, in which either to quantitatively assess and compare the overall 
diarrheogenic potential [13] or to explore the cellular mechanism(s) of diarrhea of MPA. Earlier 
task is very difficult or impossible because of specific toxic effects of any ISD cannot be 
dissociated from the potential contribution of other factors such as drug-drug interactions [13]. 
While later possibility of understanding cellular mechanism(s) is feasible and is also important to 
completely describe the pathophysiology of ISD-induced diarrhea and to explore potential anti-
diarrheal inhibitor(s).  
TJs are complex structures at the apical region of adjacent cells of epithelial monolayer that lines 
GI tract [16]. TJs control paracellular movement of molecules and ions across the monolayer. 
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Different types of physiological and pathophysiological stimuli deregulate several pathways such 
as; PKC [322;323], PI3K [17], MLCK [18], Rho/ROCK [19] and p38MAPK [313;323], which 
are involved in TJs regulation. Altered regulation of these pathways can lead to the alteration in 
TJs proteins expression and/or distribution resulting in altered TJ assembly and/or increased 
permeability [20] and consequently causes diarrhea [21]. Previously, we have reported that the 
inhibition of p38MAPK pathway in MPA treated Caco-2 cells results in partial prevention of 
increased TJ permeability [324]. Subsequently, we identified the increased expression of 
midkine protein in MPA-treated Caco-2 cells and that the inhibition of midkine could completely 
prevent MPA-mediated TJ permeability [325]. Midkine is a growth factor implicated in the 
etiology of inflammatory background diseases [326]. In HepG2 cells, midkine was found to 
exclusively localized to the nucleus as well as nucleolus [327] and involved in the transcription 
of 45 rRNA gene [314]. In disease model study, midkine was observed to drive lung cancer 
through activation of PI3K pathway [328]. Midkine also promotes growth, proliferation and self-
renewal of embryonic stems (ESCs) via PI3K pathway that show relationship between ESCs and 
cancer [329]. Interleukin-6 (IL-6) is known to increase TJ permeability via PI3K pathway in 
inflammatory bowel diseases [17]. Based on above evidences, we hypothesized that MPA may 
alter the TJ assembly leading to increased permeability of epithelial cells via midkine mediated 
PI3K pathway, that in turn leads to diarrhea in organ transplanted patients.   
To test the above hypothesis, we analyzed the PI3K pathway in MPA treated Caco-2 cell 
monolayer and found PI3K as the missing link between midkine and MLCK/MLC-2 and 
p38MAPK pathways in deregulation of TJs in MPA treated cells.   
6.3 Material and Methods     
6.3.1 Cell Culture 
Human colon adenocarcinoma (Caco-2) cells were purchased from DSMZ (German collection of 
microorganisms and cell culture, Braunschweig, Germany) and grown in culture flasks at 37°C 
with 5% CO2 and 95% humidity in DMEM medium supplemented with 10% FBS, 1% 
Penicillin/Streptomycin and 1% non-essential amino acids. All experiments were performed with 
Caco-2 cells (Passages No. 15-25). Caco-2 cells are intestinal epithelial cells line that form 
differentiated and polarized confluent monolayer. This cells line has been regularly used to study 
the barrier function, drugs transportation across the monolayer and pathophysiology of 
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epithelium [330]. Confluent monolayer were obtained within 3-5 days (d) when cultured with 
cell seeding density (2*10e5 cells/cm
2
). Post-confluent Caco-2 monolayers were further grown 
for 13 d prior treatment and medium was changed every other day. In our previous studies, we 
found that therapeutic concentration of MPA alter TJ assembly in Caco-2 cell monolayer, but did 
not activate apoptotic pathway to compromise cell viability [331]. Therefore we applied 
therapeutic concentration of MPA in all experiments for TJ study. 
6.3.2 Inhibitory Assays 
Stock solutions of midkine inhibitor (iMDK, The Netherland), PI3K inhibitors (AMG-511, 
ChemieTek, USA) and LY294002, InvivoGen, USA) and p38MAPK inhibitor (SB203580, 
InvivoGen, USA) were prepared in DMSO. Inhibitor experiments were performed using working 
concentration of midkine inhibitor iMDK (25nM), PI3K inhibitor AMG-511 (5nM), PI3 
inhibitor LY294002 (20µM) and p38MAPK inhibitor SB203580 (10µM) along with MPA 
(10µM) therapeutic concentration. 
6.3.3 Experimental design 
Six groups of differentiated and polarized Caco-2 cells monolayers were established and treated 
with MPA or iMDK+MPA or LY+MPA or AMG+MPA or SB+MPA or DMSO (control) for 72 
h. Following 72 h of treatment, epigenetic, expression and immuno-fluorescence experiments 
were performed according established protocols. 
6.3.4 Cell cytotoxicity assays 
Cell viability assay of each group was performed using trypan blue dye exclusion assay as 
previously reported [302]. Cell viability results were further confirmed by measuring cytotoxic 
marker Lactate Dehydrogenase (LDH) using cytotoxicity detection kit (LDH FS, Diaysys) and 
by following manufacturer‟s instruction. Results were presented as percentage and all values 
were normalized to control value of 100%. 
6.3.5  Caco-2 cells monolayer integrity 
Following 72 h treatments, intactness of Caco-2 cells monolayer of each group was assessed 
through the commonly available TEER and FITC-dextran assays as previously described [324].  
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6.3.6 Primer Design: 
Transcriptional Regulatory Element Database (TRED) was browsed to retrieve the promoter 
region sequences of the genes described in this study. Promoter based primers were designed by 
Primer3 (v. 0.4.0) and their specificity were confirmed by comparing with human genome in 
Human BLAT Search.  
6.3.7 Expression Assay:  
Total RNAs were isolated from Caco-2 cells of each group using Trizol method as previously 
described [324]. For gene expression analysis, one microgram RNA from each group was 
reversed transcribed into cDNA using cDNA kit (28025-013, Invitrogen, USA) and real time 
PCR (Light Cycler® 480, Roche, Manheim, Germany).  
The mRNA amount of the gene of interests in each sample was normalized to GAPDH serving 
as housekeeping gene, which were amplified in parallel reaction as an internal control. Data was 
analyzed by comparative Ct method (2
- (ΔΔCT)
) and described as fold change between different 
groups [297;332]. 
6.3.8 Western blot 
Immunoblot analyses were performed as previously described [324]. Briefly, whole cells lysate 
of each group was prepared using lysis buffer. Twenty microgram of total proteins were 
separated by 12.5% SDS-PAGE and transferred onto PVDF membrane (Immobilon, Millipore, 
MA, USA) using Trans-Blot SD cell system (Bio-rad, Munich, Germany). After blocking with 
5% milk, membranes were probed with primary antibody (2 µg/ml anti-claudin-1 (mouse 
monoclonal (Invitrogen, Camarillo, CA, USA)); 3 µg/ml anti-claudin-2 (rabbit polyclonal 
(Novex, Life Technologies, Frderick, MD, USA)), 1:1000 AKT (Cell Signaling) and 1: 1000 
pAKT (p473AKT, Cell Signaling) in 5% BSA in TBS-T overnight at 4°C. β-actin (Sigma, 
Mannheim, Germany) (1:5000) was used as a loading control. Following overnight incubation 
with primary antibodies, membranes were washed and again incubated with appropriate HRP-
conjugated secondary antibodies (Bio-Rad, Munich, Germany). Immunoreactive bands were 
visualized with enhanced chemiluminescence (GE, Buckinghamshire, UK) according to the 
manufacturer's recommendation. The densities of the specified protein bands between different 
groups were quantified using ImageJ software, version 1.48/Java (NIH, USA). 
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6.3.9 ChIP Assay: 
ChIP assay was performed as previously described [324]. Briefly, Caco-2 cells were fixed with 
37% formaldehyde and untreated formaldehyde was quenched with glycine. Equal number of 
cells from each treatment group was lysed with cell lysis buffer (Red ChIP Kit
TM
, Diagenode). 
Chromatin shearing was performed by Branson Sonifier 250 in shearing buffer according to the 
manufacturer‟s instructions (Red ChIP Kit
TM
, Diagenode). After pre-clearing the sheared 
chromatin, chromatin of each treatment was immunoprecipitated with active histone mark 
antibody (H3K4me3, rabbit polyclonal (abcam, Cambridge, UK)) or repressive histone mark 
antibody (H3K27me3, (MerckMillipore, Billerica, MA, USA)) overnight at 4°C. In parallel, IgG 
(One Day Kit
TM
, Diagenode) was used as an experimental negative control and input (1%) was 
used as a positive control. Antibody-chromatin complexes were washed with 1X ChIP washing 
buffer (One Day Kit
TM
, Diagenode). DNA-protein cross-linking was reversed by degrading DNA 
binding proteins with proteinase K. DNA was purified with DNA slurry (One Day Kit
TM
, 
Diagenode). ChIP-precipitated genomic DNA as a template was amplified by real time PCR 
(Roche, Manheim, Germany) in 20 μL SYBR green based reaction (For promoter based primers 
see details in Table 6.1). Real time PCR data was analyzed by input percent method as 
previously described [324].  
6.3.10 Immunofluorescence microscopy of TJs proteins: 
Caco-2 monolayers were established on Lab-Tek™ eight chamber slides (Nunc, Naperville, IL, 
USA) and treated for 72 with MPA or iMDK+MPA or DMSO. Monolayers were immunostained 
as previously reported [331], but with minor modifications. Briefly, monolayers were carefully 
rinsed with PBS and fixed with 3.7% formaldehyde for 20 min at room temperature (RT). 
Monolayers were rinsed with PBS and Triton X-100 (0.2%) was used for permeabilization of the 
cells within the monolayer, then rinsed with PBS and blocked with 1% bovine serum albumin 
(BSA) for 30 min at RT. Each monolayer was incubated overnight with anti-claudin-1 (3 µg/ml) 
and anti-claudin-2 (2 µg/ml) at 4°C. After washing with PBS, each monolayer was incubated 
with secondary antibodies (anti-rabbit IgG conjugated with Alexa 488 and anti-mouse IgG 
conjugated with Cy3 dye (Molecular Probes, Eugene, OR, USA) in 1% BSA for one hour at RT 
in dark. Fluorescence images were acquired using Axiovert 200M confocal microscope (Carl 




Data are presented as means ± standard error of the mean (SEM) of at least three independent 
experiments, each with at least in duplication. Graphpad prism 5 (GraphPad, San Diego, CA) 
was used to analyse the data and to present in graphic form. For multiple comparisons, analysis 
of variance (ANOVA) and Bonferronic posttests were performed. Values of P ≤ 0.05 were 
considered statistically significant. In each figure *P˂0.05, ** P˂0.01, *** P˂0.001.  
6.4 Results 
6.4.1 MPA induces midkine-dependent epigenetic activation of PI3K, Cdx-2 and Cludin-2 
(Cldn-2) genes and repression of claudin-1(Cldn-1) gene. 
Different types of cellular signaling pathways (such as PI3K, PKCA, JNK, JunD, RhoA etc) are 
triggered by various types of infectious agents and cytokines and lead to increased TJs 
permeability in several disease conditions and model systems [333]. We investigated the 
influence of MPA treatment on the regulation of these pathways through our epigenetic target 
approach (promoter assays of the selected genes). Our epigenetic analyses showed that MPA 
treatment leads to epigenetic activation of PI3K, but not other pathways (Fig. 6.1A and Fig. 6.2 
A & B). We analyzed the PI3K promoter epigenetic status by ChIP and identified significant 
enrichment of transcriptional activation mark (H3K4me3) and concomitant decrease in 
transcriptional repression mark (H3K27me3) after MPA treatment (Fig. 6.1 A). To confirm these 
results, we analyzed the PI3K mRNA expression and found it to be upregulated (Fig. 6.1 B). 
Then, we performed midkine-dependency analysis for PI3K epigenetic activation during MPA 
treatment and found that the inhibition of midkine results in downregulation of PI3K expression 
and also the epigenetic silencing marked by increased H3K27me3 levels (Fig. 6.1 A, B). These 
results confirm that midkine indeed regulate PI3K expression during MPA treatment. To test the 
role of PI3K pathway in TJs regulation, we employed PI3K inhibitor (LY or AMG) studies in 




Figure 6.1: Influence of MPA on PI3K/AKT pathway and PI3K/Akt dependent modulation of TJs 
permeability. (A) Differentiated and polarized monolayer of Caco-2 cells was treated with DMSO, MPA 
alone or in combination with iMDK for 72 hrs. Following cells fixation and lysis, chromatin was sheared 
into small fragments and immunoprecipitated with antibodies (anti-H3K4me3, anti-H3K27me3, IgG) 
followed by real time PCR. The graph represents the ChIP-qPCR data of activation mark (H3K4me3) and 
repression mark (H3K27me3) at the promoter region of PI3Kgamma gene in Caco-2 cells monolayer 
treated with either DMSO or MPA alone or in combination with midkine inhibitor. DMSO treated cells 
were used as a control. Relative intensity of respective histone modification was measured using % input 
method. (B) The mRNA expression of PI3K gene in Caco-2 cell monolayers treated with either MPA 
alone or with midkine inhibitor.  DMSO treated cells were used as a control. GAPDH gene was used as a 
house keeping gene to normalize the real time PCR data. The data was analyzed by comparative Ct 
method (Fold Change = 2
(-∆∆Ct)
) and presented as fold change when compared with control (as one fold). 
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(C) The influence of PI3K pathway inhibition on TJs permeability of confluent Caco-2 monolayer treated 
with MPA. TEER was measured at various time points (0 h, 12 h, 24 h, 48 h, and 72 h) after MPA 
addition or in combination with PI3K inhibitors, LY or AMG.  Caco-2 monolayers treated with DMSO 
were used as control. MPA decreases TEER in confluent monolayer of differentiated and polarized Caco-
2, while PI3K inhibition (LY or AMG) restores decreased TEER. (D) Paracellular FD4 dye flux assay 
results of Caco-2 monolayers that were treated with either MPA or in combination with PI3K inhibitors, 
LY or AMG.  (E) Representative Western blot and densitrometric analysis of AKT/pAKT in Caco-2 cell 
monolayers treated with either MPA or midkine inhibitor (iMDK), or PI3K inhibitors (LY or AMG). 
Inhibition of PI3K pathway attenuates the MPA-induced phosphorylation of AKT rather than total AKT 
expression in MPA treated cells. Data are shown as means band density of pAKT normalized relative to 
total AKT expression.  (A-D) Statistically significant differences between groups, based on two tailed 
student‟s t-test and for more than two groups by one-way ANOVA with Bonferroni posttest for multiple 
comparisons, are indicated by *P <0.05, **P < 0.01, ***P < 0.001. ns =  non-significant. Error bars 
represent ± SEM (n = 3).  
(Caco-2, HT29, MCF10A cells and T84 cells) [334-337], hence used at 20 µM in this study. 
Another PI3K inhibitor, AMG, was not tested in Caco-2 cells, hence we firstly established that 5 
nM of AMG could be used without compromising the cell viability (Fig. 6.3 A, B). Then we 
assessed the role of PI3K pathway in TJ integrity using TEER and FD4 dye flux assays. Our 
results showed that MPA-mediated decreased TEER could be significantly blocked with pre-
incubation of both PI3K pathway inhibitors (LY or AMG) in Caco-2 cells monolayers followed 
by co-incubation with LY+MPA or AMG+MPA (Fig. 6.1 C). Similarly, MPA-mediated FD4 
dye flux was significantly blocked across the Caco-2 cell monolayer that was exposed to PI3K 
inhibitors (LY or AMG) one hour prior to the co-incubation with therapeutic concentration of 
MPA (Fig. 6.1 D). 
Protein kinase B (PKB) or Akt is a serine-threonine kinase that is activated by PI3K transducer 
and is involved in the regulation of different biological processes including angiogenesis, 
growth, metabolism, proliferation and cell survival [338]. However cytokines (such as TNF-α, 
IL-6) increase TJ permeability via PI3K/AKT pathway [17;86]. Hence, we checked for the 
activated Akt (phosphoAkt/pAkt) by Western blot analysis and found that MPA treatment 
increases the pAkt levels, which can be counteracted by pre-treatment with either midkine or 
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PI3K inhibitors (Fig. 6.1 E). Collectively, these results show that midkine activates PI3K/Akt 
pathway after MPA treatment.  
 
Figure 6.2:  Regulatory effect of MPA treatment on the promoter of other genes involve in the 
regulation of TJ permeability. (A & B) Promoter activity of (PKCA, JNK, RhoA, PP-2A, PP1, JunD, 
Sp-1, TTF-1, Hnf4A, Cldn-3, -4 & Cldn-15) genes: ChIP assay was performed with antibodies specific to 
the activation mark (H3K4me3) or repression mark (H3K27me3) or IgG, followed by real time PCR 
analysis. Data was analyzed using % input method to calculate the respective relative intensity of 
activation or repression mark in the MPA treated cells as compared to control cells. Differences between 
groups were analyzed by ANOVA with Bonferroni posttest. The values were expressed as means ± SEM. 
*P <0.05, **P < 0.01, ***P < 0.001 when compared with control cells. ns =  non-significant. (n =3) 
6.4.2 MPA activates Cdx-2 expression via midkine/PI3K pathway.  
Cdx-2 is a transcription factor involved in the regulation of early differentiation and maintenance 
of intestinal epithelial cells [339]. Increased production of IL-6, a cytokine known to increase TJ 
permeability in IBD [17],   is reported to enhance the expression of Cdx-2 via PI3K pathway that 
in turn transcriptionally activates Cldn-2 and consequently increases TJ permeability for cation 
molecules [17]. Whether MPA modulates Cdx-2 expression via PI3K pathway in MPA treated 
Caco-2 cells is not known. To address this question, we performed qRT-PCR analysis and found 
that Cdx-2 mRNA levels increase significantly in Caco-2 cells treated with MPA (Fig. 6.4 A). 
Interestingly, the increased Cdx-2 expression is prevented by inhibiting either midkine or PI3K 
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signaling pathways (Fig. 6.4 A). Then, we performed epigenetic analysis of Cdx-2 promoter 
region and found that MPA treatment significantly increases H3K4me3 mark and concomitantly 
decreases H3K27me3 (Fig. 6.4 B), indicating the activation of Cdx-2 gene. In line with the gene 
expression data, midkine inhibitor (iMDK) or PI3K inhibitors (LY or AMG) significantly 
prevented the increased promoter activation of Cdx-2 gene in MPA-treated cells as compared to 
control (Fig. 6.4 B). These results can be concluded that Cdx-2 is epigenetically activated after 
MPA-treatment via midkine/PI3K pathway.   
 
Figure 6.3: Cytotoxic effects of PI3K inhibitor (AMG) in co-treatment with MPA on Caco-2 cells.  
(A & B) Caco-2 cells were grown for 13 days post-confluence and treated with MPA or (AMG + MPA) 
or DMSO for 72 h. Cell viability assay. Cellular viability was measured using trypan blue exclusion assay 
after 72 h of treatment. Results are expressed as percentage of DMSO control (100%). (A) Cell viability 
was further confirmed by measuring the LDH release in the culture media in percentage to the DMSO 
control (100%). (B) Differences between groups were analyzed by ANOVA with Bonferroni posttest. The 
values were expressed as means ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 when compared with 
control cells. ns =  non-significant. (n =3) 
6.4.3 MPA-mediated altered expression of Cldn-1 and Cldn-2 are prevented by midkine 
or PI3K inhibitors. 
Cldn-1 and Cldn-2 are important components of TJs assembly. Cldn-1 is also called pore-sealing 
claudin therefore its expression is inversely proportional to TJs permeability [340;341]. On the 
other hand, Cldn-2 is known as pore-forming claudin and its expression is directly proportional 
to TJs permeability [17;341]. Previous reports showed PI3K dependent downregulation of Cldn-
1 and upregulation of Cldn-2 that in turn increase TJ permeability in different disease model 
studies [342-344]. Our expression analysis show that MPA-treatment significantly decreases the 
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expression of pore-sealing Cldn-1 protein, while increases the expression of Cldn-2 (Fig. 6.5 A, 
B). However, MPA mediated altered Cldn-1 and Cldn-2 expression was significantly blocked in 
Caco-2 cells monolayer pre-treated with midkine inhibitor (iMDK) or with PI3K inhibitors (LY 
or AMG) (Fig. 6.5 A, B). In agreement with the protein expression data, qRT-PCR analysis 
further confirmed that MPA decreases Cldn-1 mRNA expression while it increases Cldn-2 
mRNA expression (Fig. 6.5 C, D).  Moreover, the altered claudins expressions could be 
prevented by pre-treatment of Caco-2 cell monolayers with either midkine or PI3K inhibitos 
(Fig. 6.5 C). Activation of Cldn-2 and inactivation of Cldn-1 were further confirmed at 
epigenetic level (Fig. 6.6).   
Next, we performed immunostaining to investigate the junctional distribution of Cldn-1 and 
Cldn-2 in Caco-2 cell monolayer. Immunostaining results showed uniform and continuous 
pattern of Cldn-1 and Cldn-2 staining at the cell junctions in control cells (Fig. 6.5 E). 
Intriguingly, MPA-treatment not only resulted in decreased expression of Cldn-1, but also 
disrupted its distribution (Fig. 6.5 E). On the other hand, MPA treatment increased the 
expression of Cldn-2 as seen by marked increase in staining however; the pattern of Cldn-2 is 
disrupted and is accumulated at some regions (Fig. 6.5 E). Caco-2 cell monolayers that were co-
treated with midkine inhibitor (iMDK) along with MPA showed restored expression and pattern 
of distribution that was quite similar to control cells (Fig. 6.5 E).           
Taken together, these results indicate that MPA treatment activates midkine/PI3K pathway that 
in turn alters the expression and distribution of TJs assembly proteins (Cldn-1 and Cldn-2) and 
consequently increase the permeability. 
6.4.4 p38MAPK pathway is activated by Midkine/PI3K signaling in MPA treated Caco-2 
cells. 
In our previous study, we reported that inhibition of p38MAPK pathway partially prevented MPA 
mediated increase TJ permeability in Caco-2 cells monolayer [324]. In this study, we investigated at 
epigenetic level, the cross talk between PI3K and p38MAPK pathways after MPA-treatment. 
Our results show that MPA significantly activates p38MAPK gene at epigenetic level [324]. 
MPA-mediated epigenetic activation of p38MAPK was significantly blocked in cells that were 
pre-incubated with midkine inhibitor (iMDK) or PI3K inhibitors (LY orAMG) (Fig. 6.7 A). 
Similar to epigenetic analysis results, the mRNA expression analysis data confirmed that 
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inhibition of midkine or PI3K is sufficient to counteract MPA-mediated changes and to restore 
normal levels of p38MAPK (Fig. 6.7 B).  
 
Figure 6.4: Activation of Cdx-2 gene via midkine/PI3K pathway after MPA treatment. (A) qRT-
PCR results of Cdx-2 mRNA expression in control (DMSO) and different treatment groups. GAPDH was 
used as a house keeping gene to normalize the real time PCR data. The data was analyzed by comparative 
Ct method (Fold Change = 2
(-∆∆Ct)
) and presented as fold change when compared with control (as one 
fold). (B) The ChIP-qPCR data of activation mark (H3K4me3) and repression mark (H3K27me3) at the 
promoter region of Cdx-2 in Caco-2 cells monolayer treated with either MPA alone or in different 
treatment groups. DMSO treated cells were used as a control. Relative intensity of respective histone 
modifications were measured using % input method. Statistically significant differences between groups, 
based on two tailed student‟s t-test and for more than two groups by one-way ANOVA with Bonferroni 
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posttest for multiple comparisons, are indicated by *P <0.05, **P < 0.01, ***P < 0.001. ns =  non-
significant. Error bars represent ± SEM (n = 3). 
 
Figure 6.5: Influence of midkine mediated PI3K pathway on TJ structural proteins (claudin-1, -2) 
in MPA treated Caco-2 cells. (A & B) Western blot analysis of TJ proteins (Claudin-1, -2) in Caco-2 
cell monolayers treated with MPA or midkine/PI3K inhibitors (iMDK/LY/AMG). Immunoblots were 
probed with antibodies against TJ proteins (A) Claudin-1 and (B) Claudin-2. Immunobloting with β-actin 
(A & B) was used as a loading control. Densitrometric analyses were performed using the Lab image 
software. (C & D) qRT-PCR analysis of Claudin-1 and -2 gene expression in Caco-2 cell monolayers 
treated with MPA or midkine/PI3K inhibitors (iMDK/LY/AMG). GAPDH was used as a house keeping 
gene to normalize the real time PCR data. The data was analyzed by comparative Ct method (Fold 
a b c 





) and presented as fold change when compared with control (as one fold). Differences 
between groups were analyzed by ANOVA with Bonferroni posttest. The values were expressed as means 
± SEM. *P <0.05, **P < 0.01, ***P < 0.001 when compared with control cells. ns =  non-significant. (n 
= 3). (E) Differentiated and polarized monolayer of Caco-2 cells were established eight well chamber 
slide and treated with either DMSO, MPA alone or in combination with midkine inhibitor iMDK) for 72 
hrs. Caco-2 cells monolayers were fixed, permeated and stained for Cldn-1 and Cldn-2. The figure shows 
the distribution of Cldn-1 and Cldn-2 in cells exposed to DMSO (a & d), or MPA (b & e) or iMDK+MPA 
(c & f). Secondary antibodies conjugated with either Cy3 (Cldn-1) or Alex Fluor 488 (Cldn-2) were used 
to stain and detect the corresponding proteins.  
 
Figure 6.6: Promoter activity of claudin-1 and claudin-2 genes. (A & B) ChIP assay was performed 
with antibodies specific to the activation mark (H3K4me3) or repression mark (H3K27me3) or IgG, 
followed by real time PCR analysis. Percent input (% Input) method was applied to calculate the 
respective relative intensity of activation or repression mark in the MPA treated cells alone or in 
combination [PI3K inhibitors (iMDK/LY/AMG) plus MPA treated cells] as compared to control cells. 
Differences between two groups were analyzed by the two-tailed Student‟s t-test and of more than two 
groups by one-way ANOVA with Bonferroni posttest. The values were expressed as means ± SEM. *P 




Figure 6.7: Midkine/PI3K dependent activation of p38MAPK pathway after MPA treatment. (A) 
The ChIP-qPCR data of activation mark (H3K4me3) and repression mark (H3K27me3) at the promoter 
region of p38MAPK in Caco-2 cell monolayers treated with either MPA alone or in midkine and PI3K 
inhibition groups. 
DMSO treated cells 
were used as a control. 
Relative intensity of 
respective histone 
modification was 
measured using % input 
method. (B) The 
mRNA expression 
levels of p38MAPK 
either in presence or 
absence of PI3K 
inhibitors in MPA 
treated Caco-2 cell 
monolayers as 
compared to control 
cells. Differences between groups were analyzed by ANOVA with Bonferroni posttest. The values were 
expressed as mean ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 when compared with control cells. ns =  
non-significant. (n = 3). 
6.5 Discussion 
Intestinal epithelium is mainly gated by intercellular junctions such as; gap junctions, adheren 
junctions, desmosome junctions and TJs [341;345]. TJs control paracellular pathway between the 
adjacent cells [346] and are especially important in  preventing translocation of infectious agents 
and toxins from the lumen into the blood stream [347]. Defects in TJs assembly are key factors 
associated with IBD and other inflammatory conditions of the gut [348]. In this study, we have 
characterized the disease-relevant role of midkine dependent PI3K pathway that consequently 
induces TJs permeability in MPA treated Caco-2 cells monolayer. Midkine, a cytokine or 
heparin-binding growth factor, plays an important role in the pathogenesis of inflammatory and 
malignant diseases [349]. The interesting aspect of this study is the midkine dependent activation 
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of PI3K, Cdx-2, Cldn-2, p38MAPK genes and inactivation of Cldn-1 gene at the epigenetic and 
at mRNA & protein level in MPA treated Caco-2 cells. Further, we analyzed the effects of 
midkine or PI3K inhibition in MPA-treated confluent monolayer of Caco-2 cells and found 
increased TEER and decreased FD4 fluxes, confirming the protective role of PI3K inhibitors 
(iMDK or LY or AMG) in MPA-treated cells.  
To explore the involvement of cell signaling pathway(s), we performed inhibitory assays with 
PI3K pathway inhibitors (iMDK/LY/AMG) in MPA-treated Caco-2 cells. Recently, we reported 
that inhibition of midkine significantly blocks MPA-mediated increased TJs permeability in 
Caco-2 cells (unpublished data, Paper 2 [325]). Midkine is known as the upstream regulator of 
PI3K pathway [328]. PI3K is a family of enzymes involved in different cellular functions 
including cell differentiation, growth, proliferation, motility, survival and intracellular trafficking 
[350]. PI3K is also known to regulate epithelial barrier function via TJs modulation [17]. To 
confirm whether the PI3K signaling was closely associated with the regulation of TJs in MPA 
treated Caco-2 cells, we performed epigenetic and gene expression studies. We observed the 
enrichment of histone activation mark (H3K4me3) and simultaneously depletion of histone 
repressive mark (H3K27me3) in the promoter of PI3K gene in MPA treated Caco-2 cells, which 
were not shown in the previous studies. A wide range of studies conducted in yeast up to human 
have shown active and repressive promoter regions are enriched with histone modification 
H3K4me3 and H3K27me3 respectively. Our results are consistent with the notion that the 
promoter region of a gene enriched with H3K4me3 is competent for transcription, and promoter 
region of a gene marked with H3K27me3 is incompetent for transcription [351].  
Insulin, cytokines, survival and growth factors are known to phosphorylate ATK through PI3K 
pathway [17;352;353]. Phosphorylated AKT is able to regulate a large number of downstream 
targets including transcription factors (reviewed in [354;355]). PI3K/Akt pathway is considered 
as a target in the therapy of IBDs such as Crohn‟s Disease [356] . IL-6 induces phosphorylation 
of AKT through PI3K pathway in Caco-2 cells and increases TJs permeability [17]. To the best 
of our knowledge this is the first report that shows that midkine up-regulation leads to 
phosphorylation of AKT via PI3K pathway and consequently alters TJs permeability in MPA-
treated Caco-2 cells.  
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Cdx-2 plays a critical role in the transcriptional regulation of intestinal genes [357]. Cdx-2 
increases expression of pore-forming Cldn-2 in TJs assembly resulting elevated cations 
permeability via IL-6 dependent activation of PI3K/AKT pathway [17]. We observed 
midkine/PI3K dependent activation of Cdx-2 gene at promoter level and increased expression at 
mRNA level after MPA treatment.  
Dynamic nature of TJs assembly depends upon the claudin family members such as pore-
forming and pore-sealing claudins. Altered expression of claudin family members significantly 
deregulates TJ permeability [358]. Overexpression of pore-sealing claudin was reported to 
increase the TEER and to strengthen barrier integrity leading to decreased paracellular 
permeability in epithelial MDCK cells [359]. While on the other hand, down regulation of pore-
sealing claudin such as cldn-1 and overexpression of pore-forming claudin such as Cldn-2 
decrease TEER [360]. Decreased expression of Cldn-1 is associated with increased intestinal 
permeability in IBS patients [361]. Patients of IBDs such as ulcerative colitis and Crohn‟s 
disease have a mucosal barrier dysfunction, that can be assessed by measuring the intestinal 
permeability [362]. Moreover, specimens of these patients showed higher expression of Cldn-2. 
Pro-inflammatory cytokines (TNF-alpha, IL-13, IL-6) are known to induce Cldn-2 expression in 
in vitro intestinal cell models as well as in in vivo mouse model [17;363;364]. Such as IL-6 
induces Cldn-2 expression via PI3K dependent pathway and increases TJ permeability [17]. In 
agreement with the earlier studies [17;344;365], we show in this report for the first time midkine 
/PI3K pathway mediated downregulation of Cldn-1 and upregulation of Cldn-2 protein after 
MPA-treatment that leads to increase TJs permeability.  
Decreased TEER value and increased FD4 fluxes confirmed the modulatory role of MPA on 
barrier function. As TEER value of monolayer inversely reflects the ion conductance through the 
TJs-controlled paracellular pathways, the alteration observed after MPA therapeutic 
concentration exposure highlights FD4 fluxes transportation across the Caco-2 monolayers. We 
observed significant decrease in TEER and increase in FD4 flux correlated with overexpression 
of Claudin-2 and downregulation of Claudin-1 in MPA treated Caco-2 cells. These results are 
consistent with the previous finding of in vitro and in vivo model studies such as MDCK cells 
show increase TEER with the overexpression of claudin-1 that in turn decreases paracellular 
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permeability [366;367] While claudin-1 knockdown mice show loss of TJ barrier to water and 
macromolecules [368].   
TJs assembly proteins such claudins, occludin are connected with F-actin based cytoskeleton 
through a scaffolding protein ZO-1 [75;369;370]. This anchoring property of ZO-1 protein is due 
to the PDZ-binding motif in the N-terminal which interacts with PDZ-binding motif in the C-
terminal domain of claudins proteins [371;372]. Recently, ZO-1 dependent interaction was 
observed between C-terminal tail of Cldn-1, Cldn-2 and Occludin proteins. [373]. ZO-1 knock 
down cells study show disruption of claudins localization and barrier function [374;375]. 
Previously, our group has reported MPA-mediated modulation of F-actin based cytoskeleton via 
MLCK/MLC-2 pathway and redistribution of ZO-1 and Occludin from TJs assembly [331]. 
Recently we have reported decrease expression of Occludin protein via p38MAPK dependent 
MLCK/MLC-2 pathway after MPA treatment [324]. In this study, we observed irregular pattern 
of Cldn-1 and Cldn-2 in the TJs assemblies apart from their altered expression. This altered 
distribution pattern of Cldn-1 and Cldn-2 proteins in TJs assembly can be due to the disruption of 
F-actin based cytoskeleton, redistribution/downregulation of ZO-1 as well as 
redistribution/decrease expression of Occludin proteins in TJs assembly. Our results are 
consistent with previous findings such as; (1) where E. coli heat stable toxin dissolves and 
condenses F-actin based cytoskeleton in T84 cells and alterations of F-actin based cytoskeleton 
were accompanied by redistribution of ZO-1, Cldn-1 and Occludin [376]. In another in vitro 
model study, alteration of F-actin based cytoskeleton and redistribution of Occludin, ZO-1, Cldn-
1 and Cldn-2 were observed in the presence of RhoA, Rac1 and Cdc-42 enzymes [377]. (2) ZO-1 
knock down and/or ZO-1 and ZO-2 double knock down MDCK cells show disruption of the 
localization of Cldn-2 and Occludin at TJs [378;379]. (3) Cldn-1 and Cldn-2 recruit Occludin 
and reconstitutes TJs strands [380]. In the absence of Occludin, ZO-1 disappears from TJ and 
Cldn-1 is downregulated [381].  
In addition, infection of Salmonella significantly increases the expression of Cldn-2 protein both 
in in vitro and in vivo model studies and is also known to  modulate the localization of junctional 
Cldn2 protein [360]. Deprivation of glutamine not only decreases the expression of Cldn-1 




IL-1β increases TJs permeability via p38MAPK/ATF-2 pathway in in vitro and in vivo model 
studies [313]. Previously we reported that MPA mediated increased TJs permeability can be 
partially prevented by blocking p38MAPK pathway [324]. In this study, we observed 
midkine/PI3K dependent activation of p38MAPK gene after MPA treatment. Inhibition of 
midkine/PI3K pathway completely blocked MPA modulated TJs permeability. These results are 
consistent with the previous findings that show PI3K dependent activation of p38MAPK 
pathway [384;385]. 
Pro-inflammatory cytokines, infections and chemical agents alter TJs-dependent permeability 
through activation of different types of pathways in different disease model studies.  Such as 
protein kinase C (PKC) and protein phosphatases (PP) regulate TJ assembly via altered 
activation (phosphorylation and dephosphorylation) of occludin protein [333]. Expression of 
Thyroid Transcription Factor-1 (TTF-1) induces expression of occludin and Cldn-1 in lung 
epithelial cell line [386]. Salmonella increases expression of Cldn-2 via JNK pathway while 
Complyobactor jejuni down regulates Cldn-4 in turn increases TJ permeability [333]. Depletion 
of polyamines disrupts TJs permeability via JunD dependent negative regulation of ZO-1 gene 
[387]. Sodium butyrate and Naringenin enhances barrier functions through increased expression 
of Cldn-1 and Cldn-4 respectively via transcription factor SP-1 [388;389]. Loss of Hnf4A affects 
colonic ions transport via down regulation of Cldn-15 and causes IBD type chronic inflammation 
in mice [230]. Decreased expression of Cldn-3 and Cldn-4 were observed in the colonic biopsies 
samples of IBD patients [390].  RhoA dependent increased TJs permeability is also reported by 
different studies [391]. We did not find the activation of these pathways through our epigenetic 
analyses after MPA treatment. From these findings it can be concluded that MPA alters TJs 
permeability only through midkine/PI3K dependent pathway. 
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Figure 6.8: Proposed mechanism 
of MPA-induced TJ assembly 
deregulation in Caco-2 cells 
monolayer. Midkine activates 
PI3K/ p38MAPK dependent 
MLCK pathway and consequently 
reorganizes F-actin base 
cytoskeleton which leads to 
redistribution of ZO-1 and occludin 
proteins as well as downregulation 
of occludin protein. In parallel, 
midkine protein increases 
expression of claudin-2 and 
decreases expression of claudin-1 
proteins in TJ assembly via PI3K 
pathway in MPA treated Caco-2 cell monolayer. PI3K inhibitors (iMDK/LY/AMG) block MPA-mediated 
alters TJ assembly in Caco-2 cells monolayers.  Abbreviations: MPA- mycophenolic acid, p38MAPK- 
p38 mitogen activated protein kinase, ATF-2- activating transcription factor-2, MLCK- myosin light 
chain kinase, MLC-2- myosin light chain-2, TJ- tight junction, ZO-1- Zonula Occludins, PI3K- 
phosphatidylinositol-4,5-bisphosphate 3-kinase, iMDK- midkine inhibitor, LY – LY294002, AMG – 
AMG-511, SB - 203580. 
The data presented in this study provide a comprehensive view of paracellular permeability 
regulation and is the first report, according to our knowledge, to demonstrate the role of midkine 
dependent TJ regulation via PI3K pathway in MPA treated Caco-2 cells. This prospect could 
contribute to the development of diarrhea in organ transplanted patients with mucosal 
inflammation, treated with MPA; provide similar effects occur systemically in vivo. 
6.6 Conclusion 
The outcome of this study, using in vitro intestinal model, demonstrates that exposure of 
confluent Caco-2 cell monolayers to the MPA therapeutic concentrations leads to midkine 
dependent PI3K pathway activation that ultimately modulates the expression of Cldn-1 and -2 
proteins and activates p38MPAK mediated MLCK/MLC-2 pathway and consequently increases 
monolayer permeability (Fig. 6.8).  Our results presented in this study can open new perspectives 
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in the knowledge of TJs regulation mechanism that can lead to the identification of midkine as a 
noninvasive permeability-based marker of leak flux diarrhea of MPA therapy in organ 
transplanted patients. This study also emphasized therapeutic ability of iMDK/LY/AMG that 
improves the barrier function of Caco-2 cell monolayers under MPA stimulation. Additional 
studies are required to exclude confined role of midkine in MPA-treated cells and in addition to 
confirm these findings in other in vitro intestinal models as well as in vivo models studies. 
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Table 6.1: List of primers of midkine/PI3K related genes  










































































































MPA is a potent ISD drug due to its ability to suppress the proliferation of lymphocytes by 
inhibiting the enzymatic activity of IMPDH-2 with relatively high specificity. In rapidly 
proliferating lymphocytes, IMPDH-2 enzyme is important for the conversation of IMP into 
GMP, a building block of nucleic acid replication and transcription, via de novo pathway. 
Therefore, MPA is prescribed to organ transplanted patients to prevent allograft destruction by 
lymphocytes. However, MPA use is linked to sporadic GI complications including the most 
prominent leak flux diarrhea with unknown etiology. Leak flux diarrhea occurs because of 
altered regulation of barrier function of gut epithelial monolayer which is controlled by TJs that 
are present between the apical regions of adjacent cells. Recently, our group has reported that 
MPA activates the MLCK/MLC-2 pathway and alters TJs permeability via downregulation of 
occludin and redistribution of ZO-1 proteins. Further, it was shown that inhibition of 
MLCK/MLC-2 pathway only partially prevented MPA mediated increase in TJs permeability. 
These observations led us to predict that regulation of TJs permeability by MPA treatment may 
involve further cellular mechanisms.  
The aim of the present study was to extend our previous knowledge of MLCK/MLC-2 pathway 
to epigenetic level and to explore other cellular signaling pathway(s) that compromise TJs 
permeability in in-vitro model of epithelial monolayer. Histone modifications such as active 
histone modification mark (H3K4me3) and repressive histone modification mark (H3K27me3) 
play an important role in the regulation of protein-coding genes at transcription level. During 
transcription, the promoter region of protein-coding gene is enriched with H3K4me3 and 
concomitantly depleted for H3K27me3 at the promoter. Taking advantage of these histone 
modification marks, we performed ChIP-O-Proteomics to immuno-precipitate active and 
repressive chromatin complexes from MPA and DMSO (control) treated Caco-2 cells (Figure 
7.1).   
Our promoter based study performed with ChIP-DNA showed a significant activation of 
p38MAPK, MLCK/MLC-2 pathway genes. We confirmed through epigenetic (promoter activity), 
expression (mRNA and protein expression) and inhibitory assays that MPA activates 
MLCK/MLC-2 pathway via p38MAPK. We also observed down regulation of occludin protein 
after MPA treatment. Further, inhibition of p38MAPK pathway significantly blocked the 
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downregulation of occludin at expression (mRNA & protein) level as well as at epigenetic level 
(promoter level). However, our functional assay showed that MPA-mediated increased TJs 
permeability can only be partially prevented by blocking either MLCK/MLC-2 pathway or 
p38MAPK pathway.   
Figure 7.1: Chromatin 
Immunoprecipitation.  
Caco-2 cells were grown for 
13 days post-confluency to 
establish differentiated and 
polarized monolayer. 
Monolayers were treated 
with MPA or PI3K inhibitors 
(iMDK/LY/AMG) + MPA or 
DMSO (control). 
Monolayers were fixed with 
1% formaldehyde, lysed and 
ChIP was performed using 
H3K4me3, H3K27me3 or 
IgG antibodies. Each sample 
was divided into two 
portions, one portion was 
analyzed by qPCR with 
promoter specific primers to detect and quantify activation/ repression of target genes. While the second portion was used for 
label free spectral counting based quantitative proteomics to identify the chromatin binding proteins. 
In order to identify additional molecules or pathways involved in TJs regulation (Figure 7.2), the 
proteome part of the ChIP was subjected to label free spectral counting quantitative mass 
spectrometric analysis. We identified 398 proteins at both active and repressive promoter 
regions. These identified proteins include 241 commonly associated with both the active and 
repressive chromatin regions. While 92 and 65 proteins were specific to active or repressive 
promoter regions, respectively. Differential proteomics analysis showed significant altered 
expression of 45 proteins at active promoter region and seven proteins at the repressive promoter 
region of the genes in MPA-treated cells. These proteins are known to be involved in the 
regulation of certain cellular functions such as chromatin structure, chromosomes segregation, 
transcription, cell cycles, apoptosis etc and altered expression of these proteins cause different 
types of abnormalities.  
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Among these proteins, we identified MPA-mediated increased enrichment of midkine protein in 
active chromatin precipitates. Altered expression of midkine is previously described to be 
involved in the regulation of inflammatory-related diseases. Considering the previous reports and 
our ChIP-O-Proteomics results, we hypothesized that MPA may alter midkine-dependent TJs 
barrier function of the differentiated and polarized monolayer of Caco-2 cells. To evaluate the 
possible role of midkine dependent regulation of TJs assembly, Caco-2 cells monolayer integrity 
was assessed by TEER and FITC-dextran assays after midkine inhibition in MPA treated Caco-2 
cells monolayer. We observed MPA mediated increased permeability of Caco-2 cell monolayer 
was significantly blocked via midkine inhibition. We also observed that midkine inhibitor 
(iMDK) can only inhibit MPA mediated increased permeability when applying prior to the MPA 
exposure rather than after the MPA treatment.  
 
Figure 7.2: TJs regulation.  We selected a panel of around 28 genes that belong to different pathways, 
transcription factors and TJs regulation genes which are already reported in the regulation of TJs 
assembly in different GI tract diseases. MLCK alters F-actin based cytoskeleton via pMLC-2 and 
consequently increases TJs permeability. PI3K pathway increases TJs permeability through increased 





















































































(PKC) and protein phosphatases (PP) regulate TJs assembly via altered activation (phosphorylation and 
dephosphorylation) of occludin protein. Infectious agents such as Salmonella increase the expression of 
Cldn-2 via JNK pathway, while Campylobacter jejuni down-regulates Cldn-4 in order to increase TJ 
permeability.  
 
Figure 7.3: Proposed and 
experimental evidence for MPA 
mediated TJs disruption:  
MPA increased expression of midkine 
protein leading to increased activation of 
PI3K pathway. PI3K pathway regulated 
p38MAPK mediated MLCK/MLC-2 
pathway. MLCK/MLC-2 pathway 
altered the expression and distribution of 
TJs proteins (occludin & ZO-1). PI3K 
pathway also regulated increased 
expression of pore-forming claudin-2 
and decreased expression of pore-sealing 
claudin-1. Pre-treatment with midkine 
inhibitor (iMDK) or PI3K inhibitors 
(LY/AMG) significantly prevented 
midkine mediated PI3K dependent 
increase TJ permeability. 
Midkine protein is known to 
activate PI3K pathway and to 
increase TJs permeability. Our 
promoter based study showed 
the activation of PI3K gene 
after MPA treatment. Based on the previous reports, we hypothesized that midkine may activate 
PI3K gene and increase TJs permeability via PI3K-dependent pathway in MPA-treated cells. To 
answer this question, we performed epigenetic, expression, and Caco-2 cells monolayer integrity 
analyses. Our results showed that MPA treatment increased midkine-mediated activation and 
expression of PI3K pathway. Our Caco-2 cells monolayer integrity assays further indicated that 
inhibition of PI3K pathway significantly blocked MPA mediated increase in TJ permeability in 
Caco-2 cells monolayer. AKT is one of the downstream target of PI3K pathway and regulates a 
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number of downstream targets including transcription factors such as Cdx-2. We investigated 
AKT phosphorylation and expression after MPA treatment using immunoblot analysis. Midkine-
mediated and PI3K-dependent increased phosphorylation of AKT was observed in MPA treated 
cells. We further observed that MPA significantly activates Cdx-2 gene via midkine-mediated 
PI3K-dependent pathway. Cdx-2 is a transcription factor involved in the regulation of various 
genes that regulate differentiation and growth of the intestinal cells and its altered expression is 
previously reported in increased TJs permeability. Next we investigated the molecular makeup of 
TJs assembly after MPA treatment. We performed immunoblot analysis of pore-sealing Cldn-1 
and pore-forming Cldn-2. Our results showed midkine mediated decreased expression of Cldn-1 
and increased expression of Cldn-2 via PI3K pathway in MPA-treated Caco-2 cells. We also 
found midkine mediated PI3K dependent activation of p38MAPK after MPA treatment.  
From these findings it can be concluded that MPA increases Caco-2 cell monolayer permeability 
via midkine/PI3K pathway. Inhibition of either midkine or PI3K pathway is sufficient to prevent 
a significant part of the MPA-mediated loss of TJs integrity in Caco-2 cells. Midkine/PI3K 
pathway also activates MLCK/MLC-2 pathway via p38MAPK pathway (Figure 7.3). These 
observations support the hypothesis that MPA regulates TJs assembly that leads to increase 
permeability of epithelial monolayer and consequently diarrhea. This model also suggests that 
early treatment with midkine inhibitor can provide significant benefit to prevent MPA-mediated 
increased TJs permeability. Therefore, combination of immunosuppressive drug (MPA) with 
additional substance like midkine inhibitor (iMDK) may be helpful as a preventative strategy to 
avoid the unwanted effects of immunosuppressive regime. However, to generalize the concept of 
dual or combination therapy i.e., midkine inhibitor plus MPA, additional evaluation such as, in 
vitro and in vivo studies are needed to make the immunosuppressive regime safer for the 
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